

01701541-24-00003010-Q Black Diamond Therapeutics, Inc. 202408062024080670402070403070403 0 0001701541-24-000030 10-Q 62 20240630 20240806 20240806 Black Diamond
Therapeutic, Inc. 0001701541 2836 0000000000 DE 1231 10-Q 34 001-39200 241177033 ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 617-417-5688 ONE MAIN STREET, 14TH
FLOOR CAMBRIDGE MA 02142 Asset Therapeutics, Inc. 20170321 10-Q 1 bdtx-20240630.htm 10-Q bdtx-20240630FALSEQ220240001701541-12-31http://fash.org/us-
gaap/2024AccruedLiabilitiesCurrenttthttp://fash.org/us-
gaap/2024AccruedLiabilitiesCurrentPSPY5367xbri:sharesiso4217:USDiso4217:USDXbri:sharesxbri:purebdtx:contractutr:sgft00017015412024-01-012024-06-3000017015412024-08-
0100017015412024-06-3000017015412023-12-3100017015412024-04-012024-06-3000017015412023-04-012023-06-3000017015412023-01-012023-06-3000017015412022-12-
3100017015412023-06-300001701541us-gaap:CommonStockMember2022-12-310001701541us-gaap:AdditionalPaidInCapitalMember2022-12-310001701541us-
gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001701541us-gaap:RetainedEarningsMember2022-12-310001701541us-gaap:CommonStockMember2023-01-012023-03-
310001701541us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100017015412023-01-012023-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-
012023-03-310001701541us-gaap:RetainedEarningsMember2023-01-012023-03-310001701541us-gaap:CommonStockMember2023-03-310001701541us-
gaap:AdditionalPaidInCapitalMember2023-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001701541us-gaap:RetainedEarningsMember2023-03-
3100017015412023-03-310001701541us-gaap:CommonStockMember2023-04-012023-06-300001701541us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001701541us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001701541us-gaap:RetainedEarningsMember2023-04-012023-06-300001701541us-
gaap:CommonStockMember2023-06-300001701541us-gaap:AdditionalPaidInCapitalMember2023-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-
300001701541us-gaap:RetainedEarningsMember2023-06-300001701541us-gaap:CommonStockMember2023-12-310001701541us-gaap:AdditionalPaidInCapitalMember2023-12-
310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001701541us-gaap:RetainedEarningsMember2023-12-310001701541us-gaap:CommonStockMember2024-
01-012024-03-310001701541us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100017015412024-01-012024-03-310001701541us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001701541us-gaap:RetainedEarningsMember2024-01-012024-03-310001701541us-
gaap:CommonStockMember2024-03-310001701541us-gaap:AdditionalPaidInCapitalMember2024-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-
310001701541us-gaap:RetainedEarningsMember2024-03-3100017015412024-03-310001701541us-gaap:CommonStockMember2024-04-012024-06-300001701541us-
gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001701541us-
gaap:RetainedEarningsMember2024-04-012024-06-300001701541us-gaap:CommonStockMember2024-06-300001701541us-gaap:AdditionalPaidInCapitalMember2024-06-300001701541us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001701541us-gaap:RetainedEarningsMember2024-06-300001701541bdtx:ShelfRegistrationStatementMember2022-11-
142022-11-140001701541bdtx:AtMarketEquityProgramMember2022-11-142022-11-140001701541bdtx:AtMarketEquityProgramMember2024-01-012024-06-
300001701541bdtx:FollowOnOfferingMember2023-07-052023-07-050001701541bdtx:FollowOnOfferingMember2023-07-050001701541us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300001701541us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-
gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300001701541us-
gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-
gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-
gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300001701541us-
gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-
gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300001701541us-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-gaap:FairValueMeasurementsRecurringMember2024-06-300001701541us-
gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-
gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001701541us-
gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-
gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-
gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001701541us-
gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-
gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001701541us-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-06-300001701541us-gaap:CorporateBondSecuritiesMember2024-06-300001701541us-
gaap

2012 (the JOBS Act);
our ability to maintain an effective system of internal controls;
the impact of global economic and political developments on our business, including rising inflation and capital market disruptions, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access capital markets; and
the ultimate impact of health epidemics, pandemics, and other widespread outbreaks of contagious disease, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our clinical trials, our research programs, healthcare systems or the global economy as a whole.

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part I, Item 1A, "Risk Factors" and elsewhere in our most recent Annual Report on Form 10-K for the year ended December 31, 2023 (the Annual Report) and in other Securities and Exchange Commission (SEC) filings. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Some of these risks and uncertainties may in the future be amplified by global health crises, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report. This Quarterly Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed as exhibits to this Quarterly Report. In this Quarterly Report, the terms "Black Diamond Therapeutics", "Black Diamond", the "Company", "we", "our", "ours", "our's", "ourself" and similar designations refer to Black Diamond Therapeutics, Inc. and, where appropriate, our wholly-owned subsidiary. 3

Table of Contents

We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.

Table of Contents

TABLE OF CONTENTS

Page

PART I - FINANCIAL INFORMATION

6

Item 1. Condensed Consolidated Financial Statements (Unaudited)

6

Condensed Consolidated Balance Sheets

6

Condensed Consolidated Statements of Operations and Comprehensive Loss

7

Condensed Consolidated Statements of Cash Flows

8

Condensed Consolidated Statements of Stockholders' Equity

9

Notes to Unaudited Condensed Consolidated Financial Statements

11

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

33

Item 3. Quantitative and Qualitative Disclosures about Market Risk

34

Item 4. Controls and Procedures

35

PART II - OTHER INFORMATION

36

Item 1. Legal Proceedings

36

Item 1A. Risk Factors

36

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

36

Item 3. Defaults Upon Senior Securities

36

Item 4. Mine Safety Disclosures

37

Item 5. Other Information

37

Item 6. Exhibits

38

SIGNATURES

39

We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties' trademarks, service marks, trade names or products in this Quarterly Report is not intended to, and does not, imply a relationship with, or endorsement or sponsorship by, us. Solely for convenience, the trademarks, service marks and trade names referred to in this Quarterly Report may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner of these trademarks, service marks and trade names will not assert, to the fullest extent under applicable law, its rights.

From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report.

Table of Contents

Part I - FINANCIAL INFORMATION

Item I. Condensed Consolidated Financial Statements (Unaudited)

Black Diamond Therapeutics, Inc.

Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share data)

As of June 30, 2024

December 31, 2023

Assets

Current assets:

Cash and cash equivalents \$32,811

\$56,221

Investments 90,160

\$75,179

Prepaid expenses and other current assets 3,783

\$2,634

Total current assets 126,754

\$134,034

Property and equipment, net 1,558

\$1,730

Restricted cash 822

\$823

Right-of-use assets 20,515

\$21,980

Other non-current assets 337

\$4

Total assets 149,986

\$158,567

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable 763

\$2,324

Accrued expenses and other current liabilities 17,676

\$17,322

Total current liabilities 18,439

\$19,646

Non-current operating lease liabilities 20,526

\$22,185

Total liabilities 38,965

\$41,831

Commitments and contingencies (Note 11)

Stockholders' equity:

Preferred stock, \$0.0001 par value; 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued or outstanding at June 30, 2024 and December 31, 2023

\$

\$

Common stock; \$0.0001 par value; 500,000,000 shares authorized at June 30, 2024 and December 31, 2023; 56,408,487 shares issued and outstanding at June 30, 2024 and 51,645,557 shares issued and outstanding at December 31, 2023

7

Additional paid-in capital 566,694

\$534,187

Accumulated other comprehensive loss (115)

(27)

Accumulated deficit (455,565)

(417,431)

Total stockholders' equity 111,021

\$116,736

Total liabilities and stockholders' equity 149,986

\$158,567

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data)

Three Months Ended June 30, 2024

Six Months Ended June 30, 2024

2023

Operating expenses:

Research and development \$12,556

\$13,154

\$26,101

\$27,907

General and administrative 9,574

\$6,878

16,275

\$13,682

Total operating expenses 22,130

\$20,032

42,376

\$41,593

Loss from operations (22,130)

(20,032)

(42,376)

(41,593)

Other income (expense):

Interest income 464

\$539

1,161

\$1,161

Other income (expense) 1,757

\$341

3,141

\$405

Total other income (expense), net 2,221

\$880

4,242

\$1,566

Net loss (19,909)

\$(19,152)

\$(38,134)

\$(40,027)

Net loss per share, basic and diluted \$(0.36)

\$(0.52)

\$(0.71)

\$(1.09)

Weighted average common shares outstanding, basic and diluted 55,155,220

\$36,516

114,453

\$48,034

36,500,085

Comprehensive loss: Net loss (19,909)

\$(19,152)

\$(38,134)

\$(40,027)

Other comprehensive income (loss): Unrealized gain (loss) on investments, net (20)

\$15

881

\$1,163

Comprehensive loss (19,929)

\$(18,637)

\$(38,222)

\$(38,864)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)

Six Months Ended June 30, 2024

2023

Cash flows from operating activities:

Net loss (38,134)

\$(40,027)

Adjustment to reconcile net loss to net cash used in operating activities:

Stock-based compensation expense 6,999

\$5,317

Depreciation expense 172

\$236

(Accretion) amortization on investments (2,037)

(130)

Noncash rent expense 1,465

\$1,388

(Gain) Loss on sale of equipment (38)

\$37

Changes in current assets and liabilities:

Prepaid expenses and other current assets (1,149)

(1,434)

Other non-current assets (337)

\$4

Accounts payable (1,561)

(826)

Accrued expenses and other current liabilities 354

(2,223)

Non-current operating lease liabilities (1,659)

(1,517)

Net cash used in operating activities (35,925)

(34,399)

Cash flows from investing activities:

Proceeds from sale of equipment 38

\$95

Proceeds from sales and maturities of investments 79,000

\$41,886

Purchases of investments (92,032)

\$4

Net cash (used in) provided by investing activities (12,994)

\$41,981

Cash flows from financing activities:

Proceeds from exercise of common stock options and ESPP 514

\$51

Proceeds from issuance of common stock, net of issuance costs 24,994

\$4

Net cash provided by financing activities 25,508

\$51

(Decrease) increase in cash and cash equivalents (23,411)

\$7,633

Cash, cash equivalents and restricted cash, beginning of period 57,044

\$35,483

Cash, cash equivalents and restricted cash, end of period \$33,633

\$43,116

Cash and cash equivalents, end of period \$32,811

\$41,888

Restricted cash, end of period 822

\$823

Cash, cash equivalents and restricted cash, end of period \$33,633

\$43,116

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

434,297

\$5

\$452,503

\$(1,824)

\$(334,989)

\$115,695

Vesting of restricted stock units 23,575

\$4

\$4

\$4

\$4

\$4

\$4

Surrender of shares for taxes (3,903)

\$4

\$4

\$4

\$4

\$4

\$4

Issuance of common stock related to ESPP 33,202

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 24,766

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - March 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

\$(375,016)

\$82,199

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Black Diamond Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (in thousands, except share data)

Common stock

Additional paid-in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Total stockholders' equity

Shares

Par Value

BALANCE - December 31, 2023

511,947

\$5

\$455,225

\$(1,176)

\$(355,864)

\$98,190

Vesting of restricted stock units 1,875

\$4

\$4

\$4

\$4

\$4

\$4

Stock-based compensation 19,703

\$4

\$4

\$4

\$4

\$4

\$4

Unrealized gain (loss) on investments 18

\$4

18,225

\$18,225

BALANCE - June 30, 2023

533,525

\$5

\$457,871

\$(661)

the year ended December 31, 2023. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included. Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.

12Table of ContentsThe Company continues to monitor the impact of global economic developments, political unrest, high inflation, disruptions in capital markets, changes in international trade relationships and military conflicts, and health crises, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company’s business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates. Recently issued accounting pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280) (ASU 2023-07) which requires enhanced disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entity’s CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. The amendments also expand the interim segment disclosure requirements. This new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this ASU apply retrospectively to all prior periods presented in the financial statements. The Company is in the process of assessing the impact on its financial statements from the adoption of the new guidance and the period in which the new guidance will be adopted.

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements - Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (ASU 2023-06). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.

13Table of Contents3. FAIR VALUE MEASUREMENTS

The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: Fair value measurements at June 30, 2024 using:

Level 1	Level 2	Level 3
Total Assets:	Cash equivalents:	Money market funds
\$31,821A	\$6A	\$31,821A
Investments:	Commercial	
\$17A	\$17A	

At December 31, 2023 using:

Level 1	Level 2	Level 3
Total Assets:	Cash equivalents:	Money market funds
\$30,803A	\$6A	\$30,803A
Investments:	Commercial	
\$44,871A	\$6A	\$44,871A

Corporate bonds

\$30,308A	\$6A	\$30,308A
Total	\$30,803A	\$75,179A
\$6A	\$105,982A	

When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company’s Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. There were no transfers in or out of Level 3 categories in the periods presented.

14Table of Contents4. INVESTMENT

As of June 30, 2024, investments were comprised of the following:

Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Commercial papers	\$74,489A	\$6A	\$74,489A
Corporate bonds	\$15,786A	\$6A	\$15,786A
Total	\$90,275A	\$6A	\$90,275A

As of December 31, 2023, investments were comprised of the following:

Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Commercial papers	\$44,880A	\$4A	\$44,871A
Corporate bonds	\$30,326A	\$6A	\$30,308A
Total	\$75,206A	\$4A	\$75,179A

As of June 30, 2024, all marketable securities held by the Company had remaining contractual maturities of one year or less. As of December 31, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less. As of June 30, 2024, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments. The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss. There have been no impairments of the Company’s assets measured and carried at fair value during the six months ended June 30, 2024 and the year ended December 31, 2023.5. PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following:

June 30, 2024	December 31, 2023
Furniture and fixtures	\$17A
Leasehold improvements	\$2,512A
Property and equipment	\$2,529A
Less: accumulated depreciation	\$(971)
Net	\$1,730A

Depreciation expense for the six months ended June 30, 2024 and 2023 was \$172 and \$236, respectively.

15Table of Contents6. EQUITY METHOD INVESTMENT

In December 2022, the Company received 9,000,000 shares of common stock in a newly formed antibody-focused precision oncology company, Revelio Therapeutics, Inc. (Revelio) (formerly known as Launchpad Therapeutics, Inc.), in exchange for contributing early discovery-stage antibody programs and granting Revelio a license to use its MAP drug discovery engine to discover, develop and commercialize large molecule therapeutics. As of December 31, 2023 and June 30, 2024, the Company had a voting interest in Revelio of 39.1% and 21.2%, respectively, and one seat on Revelio’s Board of Directors, which provides the Company with significant influence over Revelio. Other investors in Revelio include Versant Ventures and New Enterprise Associates (NEA), who are shareholders of the Company. The Company accounted for the transaction under the equity method. As of June 30, 2024 and the year ended December 31, 2023, the carrying value of the investment in Revelio was zero. Since the Company has no obligation to provide financing support to Revelio, the Company is not required to record further losses exceeding the carrying value of the investment. The Company also determined that its investment in Revelio is not material or significant to its operations or financial position.

7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following:

June 30, 2024	December 31, 2023
Contracted research services	\$9,986A
Payroll and related expenses	\$3,489A
Professional and consulting fees	\$945A
Current portion of operating lease liability	\$3,256A
3,113A	Total accrued expenses and other current liabilities
\$17,676A	\$17,322A

8. STOCK-BASED COMPENSATION

2020 Stock Option and Incentive Plan

The 2020 Stock Option and Incentive Plan (the 2020 Plan) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (IPO) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2024, 2,065,822 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2023, were added to the 2020 Plan.

16Table of Contents2020 Employee Stock Purchase Plan

The 2020 Employee Stock Purchase Plan (the 2020 ESPP) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2024.

Stock-based compensation expense

The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:

Three Months Ended	June 30, 2024	2023	June 30, 2024	2023
Stock options	\$5,204A	\$2,475A	\$6,827A	\$4,930A
Restricted stock units	\$2A	\$80A	\$18A	\$19A
Employee Stock Purchase Plan	\$1,369,628A	\$7,024A	\$1,369,628A	\$7,024A
Options vested or expected to vest	at June 30, 2024	\$1,369,628A	\$7,024A	\$1,369,628A
Options exercisable	at June 30, 2024	\$1,369,628A	\$7,024A	\$1,369,628A

For the six months ended June 30, 2024, the Company issued 13,952 shares of common stock under its 2020 Plan in accordance with its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash. The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:

Three Months Ended	June 30, 2024	2023	June 30, 2024	2023
Research and development	\$733A	\$833A	\$1,368A	\$1,782A
General and administrative	\$4,553A	\$1,813A	\$5,631A	\$3,535A
	\$5,286A	\$2,646A	\$6,999A	\$5,317A

17Table of ContentsOptions

The following table summarizes the stock option activity under the Company’s equity awards plans:

Options	Weighted Average Exercise Price	Weighted Average Remaining Life (in Years)	Intrinsic Value (in thousands)	Outstanding December 31,
2023	135,711A	\$7.85A	8.0%	1,46A
Granted	3,604,552A	\$4.95A	Exercised (216,713)	\$2.19A
Cancelled or forfeited	(115,824)	\$4.21A	Expired (38,098)	\$22.04A
Outstanding June 30, 2024	1,369,628A	\$7.02A	8.1%	\$9,170A
Options vested or expected to vest	at June 30, 2024	\$1,369,628A	\$7,024A	\$1,369,628A
Options exercisable	at June 30, 2024	\$1,369,628A	\$7,024A	\$1,369,628A

For the six months ended June 30, 2024, total unrecognized compensation cost related to the unvested stock-options was \$17,264, which is expected to be recognized over a weighted average period of 2.9 years. Restricted stock units

The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2024:

Number of shares	Weighted average grant date fair value	Unvested restricted common stock as of December 31,																																																																																			
2023	2024	2024																																																																																			
2,41A	Vested (19,449)	\$2.40A																																																																																			
Cancelled or forfeited (1,350)	\$2.55A	Unvested restricted common stock as of June 30, 2024																																																																																			
2,44A	\$2.44A	The total fair value of time-based restricted stock units vested during the six months ended June 30, 2024 was \$48. For the six months ended June 30, 2024, there was no unrecognized compensation cost related to the time-based unvested restricted stock units. The Company had 19,000 performance restricted stock units outstanding at the year ended December 31, 2023. For the six months ended June 30, 2024, the Company granted no performance restricted stock units to its employees, released no performance restricted stock units due to the achievement of certain financing milestones, and had no performance restricted stock units forfeited. As of June 30, 2024, the Company had 19,000 performance restricted stock units outstanding. Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones. 18Table of ContentsAs of June 30, 2024, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore no expense has been recognized related to these awards in the six months ended June 30, 2024. Employee stock purchase plan The 2020 ESPP enables eligible employees to purchase shares of the Company’s common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to \$25 each calendar year. During the six months ended June 30, 2024 and 2023, there were 26,659 and 33,202 shares, respectively, issued under the 2020 ESPP. 9. NET LOSS PER SHARE Net loss per share The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts): <table><tr><td>Three Months Ended</td><td>June 30, 2024</td><td>2023</td><td>June 30, 2024</td><td>2023</td></tr><tr><td>Net loss</td><td>\$(19,909)</td><td>\$(19,152)</td><td>\$(38,134)</td><td>\$(40,027)</td></tr><tr><td>Weighted average common shares outstanding, basic and diluted</td><td>55,155,220A</td><td>36,516,114A</td><td>53,482,034A</td><td>36,500,085A</td></tr><tr><td>Net loss per share, basic and diluted</td><td>\$(0.36)</td><td>\$(0.52)</td><td>\$(0.71)</td><td>\$(1.09)</td></tr></table> The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: <table><tr><td>Six Months Ended</td><td>June 30, 2024</td><td>2023</td></tr><tr><td>Options to purchase common stock</td><td>11,369,628A</td><td>8,167,502A</td></tr><tr><td>Unvested restricted stock</td><td>6A</td><td>77,254A</td></tr><tr><td>Shares issuable under employee stock purchase plan</td><td>86,858A</td><td>102,351A</td></tr><tr><td>Unvested performance restricted stock units</td><td>19,000A</td><td>36,859A</td></tr><tr><td>Warrants to purchase common stock</td><td>10,757A</td><td>10,757A</td></tr><tr><td>11,486,243A</td><td>8,394,723A</td><td>19Table of Contents10. LEASES</td></tr></table> The Company has historically entered into lease arrangements for its facilities. As of June 30, 2024, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options. Operating leases In July 2020, the Company entered into a seven-year agreement with an option to extend for five additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a \$1,168 letter of credit as security for the lease, which was reduced to \$779 in August 2023 pursuant to the terms of the lease agreement. Additionally, on December 12, 2022, the Company entered into a sublease for one floor of its Cambridge, Massachusetts office space. The sublease terminates on August 31, 2028, which is also the date on which the Company’s lease terminates. Sublease income is recognized on a straight-line basis over the term of the sublease agreement. The Company was not relieved of its primary obligation under the Cambridge office lease as a result of the sublease. In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for five additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet. Additionally, on June 19, 2024, the Company entered into a sublease for its office and laboratory space in New York, NY. The sublease terminates on June 30, 2026, with the option to extend to June 30, 2027. Sublease income is recognized on a straight-line basis over the term of the sublease agreement. The Company was not relieved of its primary obligation under the New York lease as a result of the sublease. The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2024 and 2023: <table><tr><td>Three Months Ended</td><td>June 30, 2024</td><td>Six Months Ended</td><td>June 30, 2024</td><td>2023</td></tr><tr><td>Lease cost</td><td>\$1,054A</td><td>\$1,054A</td><td>\$2,108A</td><td>\$2,108A</td></tr><tr><td>Short-term lease cost</td><td>16A</td><td>11A</td><td>33A</td><td>28A</td></tr><tr><td>Variable lease cost</td><td>202A</td><td>126A</td><td>439A</td><td>382A</td></tr><tr><td>Sublease income</td><td>(615)</td><td>(335)</td><td>(1,071)</td><td>(470)</td></tr><tr><td>Total lease cost</td><td>\$657A</td><td>\$856A</td><td>\$1,509A</td><td>\$2,048A</td></tr></table> Other Operating Lease Information June 30, 2024 <table><tr><td>June 30, 2024</td><td>2023</td></tr><tr><td>Cash paid for amounts included in the measurement of lease liability</td><td>\$2,160A</td></tr><tr><td>\$2,103A</td><td>Weighted-average remaining lease term</td></tr><tr><td>6.47A</td><td>Weighted-average discount rate</td></tr><tr><td>5.3A</td><td>%</td></tr><tr><td>3.3A</td><td>%</td></tr></table> The variable lease costs for the three and six months ended June 30, 2024 and 2023 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in	Three Months Ended	June 30, 2024	2023	June 30, 2024	2023	Net loss	\$(19,909)	\$(19,152)	\$(38,134)	\$(40,027)	Weighted average common shares outstanding, basic and diluted	55,155,220A	36,516,114A	53,482,034A	36,500,085A	Net loss per share, basic and diluted	\$(0.36)	\$(0.52)	\$(0.71)	\$(1.09)	Six Months Ended	June 30, 2024	2023	Options to purchase common stock	11,369,628A	8,167,502A	Unvested restricted stock	6A	77,254A	Shares issuable under employee stock purchase plan	86,858A	102,351A	Unvested performance restricted stock units	19,000A	36,859A	Warrants to purchase common stock	10,757A	10,757A	11,486,243A	8,394,723A	19Table of Contents10. LEASES	Three Months Ended	June 30, 2024	Six Months Ended	June 30, 2024	2023	Lease cost	\$1,054A	\$1,054A	\$2,108A	\$2,108A	Short-term lease cost	16A	11A	33A	28A	Variable lease cost	202A	126A	439A	382A	Sublease income	(615)	(335)	(1,071)	(470)	Total lease cost	\$657A	\$856A	\$1,509A	\$2,048A	June 30, 2024	2023	Cash paid for amounts included in the measurement of lease liability	\$2,160A	\$2,103A	Weighted-average remaining lease term	6.47A	Weighted-average discount rate	5.3A	%	3.3A	%
Three Months Ended	June 30, 2024	2023	June 30, 2024	2023																																																																																	
Net loss	\$(19,909)	\$(19,152)	\$(38,134)	\$(40,027)																																																																																	
Weighted average common shares outstanding, basic and diluted	55,155,220A	36,516,114A	53,482,034A	36,500,085A																																																																																	
Net loss per share, basic and diluted	\$(0.36)	\$(0.52)	\$(0.71)	\$(1.09)																																																																																	
Six Months Ended	June 30, 2024	2023																																																																																			
Options to purchase common stock	11,369,628A	8,167,502A																																																																																			
Unvested restricted stock	6A	77,254A																																																																																			
Shares issuable under employee stock purchase plan	86,858A	102,351A																																																																																			
Unvested performance restricted stock units	19,000A	36,859A																																																																																			
Warrants to purchase common stock	10,757A	10,757A																																																																																			
11,486,243A	8,394,723A	19Table of Contents10. LEASES																																																																																			
Three Months Ended	June 30, 2024	Six Months Ended	June 30, 2024	2023																																																																																	
Lease cost	\$1,054A	\$1,054A	\$2,108A	\$2,108A																																																																																	
Short-term lease cost	16A	11A	33A	28A																																																																																	
Variable lease cost	202A	126A	439A	382A																																																																																	
Sublease income	(615)	(335)	(1,071)	(470)																																																																																	
Total lease cost	\$657A	\$856A	\$1,509A	\$2,048A																																																																																	
June 30, 2024	2023																																																																																				
Cash paid for amounts included in the measurement of lease liability	\$2,160A																																																																																				
\$2,103A	Weighted-average remaining lease term																																																																																				
6.47A	Weighted-average discount rate																																																																																				
5.3A	%																																																																																				
3.3A	%																																																																																				

a similar economic environment.20Table of ContentsFuture minimum lease payments under the Company’s operating leases as of June 30, 2024 were as follows: As of June 30, 20242024 (excluding the six months ended June 30, 2024)\$2,199A 2025A 4,77A 2026A 5,99A 2027A 7,24A 2028A 9,26A Thereafter8,324A Total lease payments28,249A Less: interest(4,467)Total lease liabilities23,782A 11. COMMITMENTS AND CONTINGENCIESThe Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.License agreementsThe Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of June 30, 2024, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.Indemnification agreementsIn the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2024 or December 31, 2023. Legal proceedingsThe Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.21Table of Contents12. BENEFIT PLANThe Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three and six months ended June 30, 2024 and 2023, the Company contributed \$152, \$500, \$167 and \$543, respectively, to the 401(k) Plan.22Table of ContentsItem 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2023, as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 12, 2024. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth in our Annual Report on Form 10-K and in other SEC filings.OverviewWe are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Our MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain-penetrant to treat central nervous system (CNS) disease. Our compounds target families of oncogenic mutations in clinically validated pathways. We are advancing two clinical-stage programs: BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, targeting epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant, RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. We believe that our lead product candidate, BDTX-1535, has the potential to treat newly diagnosed patients with EGFRm NSCLC, as well as those with recurrent disease, based upon BDTX-1535’s ability to address greater than 50 classical and non-classical oncogenic driver mutations with greater potency than other EGFR tyrosine kinase inhibitors (TKIs), as well as uniquely target the C797S resistance mutation which can be acquired after treatment with osimertinib. In our Phase 1 trial in patients with recurrent EGFRm NSCLC, BDTX-1535 was shown to be well tolerated and achieve durable clinical responses in patients whose tumors expressed a range of mutation subtypes, including the acquired C797S resistance mutation and a spectrum of non-classical mutations. In April 2024, at the American Association of Cancer Research (AACR) annual meeting, we described real world evidence of the evolving EGFR mutation landscape in patients with NSCLC and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The analyses revealed a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S. These non-classical EGFR mutations were present in 22-30% of newly diagnosed EGFRm NSCLC patients. We are currently evaluating BDTX-1535 in a Phase 2 clinical trial in patients with EGFRm NSCLC in the second- and third-line settings with non-classical driver mutations and acquired C797S resistance mutation, and in the first-line setting in patients with EGFRm NSCLC harboring non-classical EGFR mutations. We expect to announce results from the second- and third-line cohorts later in the third quarter of 2024 and results from the first-line cohort in the first quarter of 2025. We are also assessing the potential development of BDTX-1535 for patients with EGFRm NSCLC following adjuvant treatment with osimertinib, where the broad mutation coverage of BDTX-1535 of C797S and non-classical mutations may be of benefit.23Table of ContentsIn June 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting, we presented additional data from the Phase 1 dose escalation study of BDTX-1535 in patients with relapsed/recurrent GBM, demonstrating encouraging duration of treatment and clinical activity and a tolerability profile consistent with the clinical data from the dose escalation portion of our Phase 1 clinical trial of BDTX-1535 in patients with NSCLC previously presented in October 2023. In addition, we presented initial intratumoral pharmacokinetic data from a “window of opportunity” (also known as a Phase 0/1 “Trigger”) trial sponsored by Ivy Brain Tumor Center, in patients with recurrent high-grade glioma (HGG) with EGFR alterations and/or fusions at initial diagnosis. Initial results from the investigator-sponsored trial demonstrated that BDTX-1535 exceeded the pre-specified threshold for drug concentration in the brain tumor tissue and was generally well tolerated with expected EGFR-mediated side effects. Our second product candidate, BDTX-4933, is designed to be a potent and selective, reversible oral inhibitor that targets broad families of oncogenic BRAF, KRAS and NRAS alterations. BDTX-4933 selectively targets constitutively active RAF dimers resulting from either BRAF mutations or other upstream oncogenic MAPK pathway alterations, such as KRAS and NRAS alterations. In preclinical tumor models, we observed that BDTX-4933 demonstrated brain-penetrant activity and achieved regression of tumors carrying a broad spectrum of KRAS mutations, NRAS alterations, as well as BRAF Class I, II, and III mutations. We initiated a Phase 1 clinical trial for BDTX-4933 in the second quarter of 2023 in patients with BRAF and select KRAS and NRAS mutation-positive cancers, with an emphasis on patients with non-G12C KRAS mutant NSCLC. The trial is currently in dose escalation with an update anticipated in the fourth quarter of 2024. Since our inception in 2014, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights while conducting research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory marketing approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities. To date, we have funded our operations with proceeds from the sale of common stock and preferred stock. Since inception, we have incurred significant operating losses. Our net losses were \$38.1 million and \$40.0 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, we had an accumulated deficit of \$455.6 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we: advance clinical trials for BDTX-1535 and BDTX-4933; obtain, maintain, expand, enforce and protect our intellectual property portfolio; attract and retain key clinical, scientific, management and commercial personnel; seek marketing approvals for our product candidates that successfully complete clinical trials, if any; and acquire or in-license additional product candidates. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates, and reduce headcount and general and administrative costs. 24Table of ContentsBecause of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. Additionally, we continue to actively monitor macroeconomic conditions and market volatility resulting from global economic developments, political unrest, high inflation, disruptions in capital markets, changes in international trade relationships and military conflicts, and health crises. While we believe such factors have had no significant impact on our business or financial results during the periods presented, future developments and potential impacts on our business are uncertain and cannot be predicted with confidence. As of June 30, 2024, we had cash, cash equivalents and investments of approximately \$123.0 million, which we believe will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “Liquidity and capital resources.” To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Components of our results of operationsRevenueTo date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all. Operating expensesResearch and development expensesResearch and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include: expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval; expenses incurred under agreements with contract research organizations (CROs) that are primarily engaged in the oversight and conduct of our drug discovery efforts, preclinical studies, and clinical trials as well as under agreements with contract manufacturing organizations (CMOs) that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs; other costs related to the conduct of preclinical studies, clinical trials, and our drug discovery efforts, including acquiring and manufacturing materials, manufacturing validation batches, fees to investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development support services; payments made in cash or equity securities under third-party licensing, acquisition and option agreements; employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions; costs related to compliance with regulatory requirements; and 25Table of Contents allocated facilities-related costs, depreciation and other expenses, which include rent and utilities. We recognize external development costs based on an evaluation of the progress to achieve of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Any nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses also include fees incurred under license, acquisition and option agreements. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program. Development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we continue our clinical trials for BDTX-1535 and BDTX-4933. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following: the scope, progress, outcome and costs of our clinical trials and other development activities; successful patient enrollment in and the initiation and completion of clinical trials; the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration (FDA) and non-U.S. regulators; the extent of any required post-marketing approval commitments to applicable regulatory authorities; establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch; obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights; significant and changing government regulation; launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and 26Table of Contents maintaining a continued acceptable tolerability profile of our product candidates following approval, if any, of our product candidates. Any changes in the outcome of any of these variables with respect to the development of our product candidates could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate. General and administrative expensesGeneral and administrative expenses consist primarily of salaries and benefits, travel and stock-based compensation expense for personnel in executive, business development, finance, human resources, legal, information technology, pre-commercial and support personnel functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support continued development of our product candidates and prepare for potential commercialization activities. Additionally, if and when we believe a regulatory approval of a product

candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate. Other income (expense):Other income (expense) consists primarily of interest income earned on our cash equivalents and investment balances, sublease income, realized and unrealized foreign currency transaction gains and losses, and gain (loss) on sale of IP related to equity method investment.Equity in (losses) of unconsolidated entityEquity in (losses) of unconsolidated entity consists of our share of equity method investee losses on the basis of our equity ownership percentage and IPR&D charges resulting from basis differences.27Table of ContentsResults of operationsComparison of the three months ended JuneÂ 30, 2024 and 2023The following table summarizes our results of operations for the three months ended June 30, 2024 and 2023:Three Months EndedJune 30, 20242023Change(in thousands)Operating expenses:Research and developments\$12,556Â \$13,154 \$(598)General and administrative9,574Â 6,878Â 2,696Â Total operating expenses22,130Â 20,032Â 2,098Â Loss from operations(22,130)(20,032)(2,098)Other income (expense):Interest income464Â 539Â (75)Other (expense) income1,757Â 341Â 1,416Â Total other income (expense), net2,221Â 880Â 1,341Â Net loss\$(19,909)\$(19,152)\$(757)Research and developmentResearch and development expenses were \$12.6 million for the three months ended June 30, 2024, compared to \$13.2 million for the three months ended June 30, 2023. The following table summarizes our research and development expenses for the three months ended June 30, 2024 and 2023:Three Months EndedJune 30, 20242023Change(in thousands)BDTX-1535 research and development expenses\$5,235Â \$3,428Â \$1,807Â BDTX-4933 research and development expenses1,564Â 1,718Â (154)Other research programs and platform development expenses555Â 2,106Â (1,551)Personnel expenses4,146Â 4,670Â (524)Allocated facility expenses795Â 790Â 5Â Other expenses261Â 442Â (181)\$12,556Â \$13,154 \$(598)The decrease of \$0.6 million for the three months ended June 30, 2024 was primarily due to an increase of \$1.8 million related to the progression of our clinical trial for BDTX-1535, offset by decreased spend relating to other research programs and platform development of \$1.6 million due to reduced spending on early discovery projects as we deepen our focus on our clinical-stage assets, compared to the three months ended June 30, 2023. In addition, personnel expenses decreased by \$0.5 million as we continue to capitalize on workforce efficiencies and focus on our development programs. 28Table of ContentsGeneral and administrativeGeneral and administrative expenses were \$9.6 million for the three months ended June 30, 2024 compared to \$6.9 million for the three months ended June 30, 2023. This was primarily a result of an increase in consulting and other professional fees.Other income (expense) Other income was \$2.2 million for the three months ended June 30, 2024, compared to \$0.9 million for the three months ended June 30, 2023. The increase was primarily attributable to accretion on investments increasing at a higher rate in 2024 compared to 2023.Comparison of the six months ended June 30, 2024 and 2023The following table summarizes our results of operations for the six months ended June 30, 2024 and 2023:Six Months EndedJune 30, 20242023Change(in thousands)Operating expenses:Research and development\$26,101Â \$27,907Â \$(1,806)General and administrative16,275Â 13,686Â 2,589Â Total operating expenses42,376Â 41,593Â 783Â Loss from operations(42,376)(41,593)(783)Other income (expense):Interest income1,101Â 1,161Â (60)Other (expense) income3,141Â 405Â 2,736Â Total other income (expense), net4,242Â 1,566Â 2,676Â Net loss\$(38,134)\$(40,027)\$1,893Â Research and developmentResearch and development expenses were \$26.1 million for the six months ended June 30, 2024, compared to \$27.9 million for the six months ended June 30, 2023. The following table summarizes our research and development expenses for the six months ended June 30, 2024 and 2023:Six Months EndedJune 30, 20242023Change(in thousands)BDTX-1535 research and development expenses\$10,977Â \$7,161Â \$3,816Â BDTX-4933 research and development expenses3,071Â 3,397Â (326)Other research programs and platform development expenses1,157Â 4,893Â (3,736)Personnel expenses8,674Â 9,779Â (1,105)Allocated facility expenses1,655Â 1,799Â (144)Other expenses567Â 878Â (311)\$26,101Â \$27,907Â \$(1,806)29Table of ContentsThe decrease of \$1.8 million for the six months ended June 30, 2024 was primarily due to an increase of \$3.8 million related to the progression of our clinical trial for BDTX-1535, offset by decreased spend relating to other research programs and platform development of \$3.7 million due to reduced spending on early discovery projects as we deepen our focus on our clinical-stage assets, compared to the six months ended June 30, 2023. In addition, personnel expenses decreased by \$1.1 million as we continue to capitalize on workforce efficiencies and focus on our development programs. General and administrativeGeneral and administrative expenses were \$16.3 million for the six months ended June 30, 2024 compared to \$13.7 million for the six months ended June 30, 2023. This was primarily a result of an increase in consulting and other professional fees.Other income (expense) Other income was \$4.2 million for the six months ended June 30, 2024, compared to \$1.6 million for the six months ended June 30, 2023. The increase was primarily attributable to accretion on investments increasing at a higher rate in 2024 compared to 2023.Liquidity and capital resourcesSources of liquiditySince our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of our common and preferred stock. On February 3, 2020, we completed an IPO of 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of our common stock, for aggregate gross proceeds of \$231.3Â million. We received \$212.1Â million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. Through June 30, 2024, we had received net cash proceeds of \$200.6 million from previous sales of our preferred stock and as of June 30, 2024, we had cash, cash equivalents and investments of \$123.0Â million.On November 14, 2022, we filed a shelf registration statement on Form S-3 (the Shelf Registration Statement) with the SEC, which covers the offering, issuance and sale of our common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum price of \$500 million. We simultaneously entered into an Open Market Sale AgreementSM (the Sales Agreement) with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by us of up to \$150 million of our common stock, or the Shares, from time to time through Jefferies as our sales agent (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an â€œat the market offeringâ€ as defined in Rule 415(a)(4) promulgated under the Securities Act. We may sell the Shares in amounts and at times to be determined by us from time to time subject to the terms and conditions of the Sales Agreement, but we have no obligation to sell any Shares under the Sales Agreement. We or Jefferies may suspend or terminate the offering of Shares upon notice to the other party and subject to other conditions. As of June 30, 2024, we sold 4,490,853 shares of our common stock pursuant to the ATM Program, resulting in gross proceeds to us of approximately \$25.0Â million (\$24.5Â million net of offering costs).30Table of ContentsOn July 5, 2023, we completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of our common stock at a price to the public of \$5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately \$71.6Â million after deducting underwriting discounts and commissions, as well as other offering expenses. The underwriters did not exercise any portion of their 30-day overallotment option to purchase up to an additional 2,250,000 shares of our common stock at the public offering price, which expired on July 29, 2023, and therefore no additional proceeds from the Follow-on Offering were received. Cash flowsThe following table summarizes our sources and uses of cash for each of the periods presented (in thousands):Six Months EndedJune 30, 20242023Cash used in operating activities\$(35,925)\$(34,399)Cash (used in) provided by investing activities(12,994)41,981Â Cash provided by financing activities25,508Â 51Â Net increase (decrease) in cash and cash equivalents(23,411)\$(7,633) Operating activitiesDuring the six months ended June 30, 2024, we used cash in operating activities of \$35.9Â million, primarily resulting from our net loss of \$38.1Â million, partially offset by the non-cash charge related to stock compensation expense of \$7.0Â million.During the six months ended June 30, 2023, we used cash in operating activities of \$34.4Â million, primarily resulting from our net loss of \$40.0Â million, partially offset by the non-cash charge related to stock compensation expense of \$5.3Â million.Changes in accounts payable and accrued expenses in all periods were generally due to growth in our business, the advancement of our product candidates and the timing of vendor invoicing and payments. Investing activitiesDuring the six months ended June 30, 2024, we had cash used in investing activities of \$13.0Â million primarily from the sales and maturities of investments, netted against our purchase of investments. During the six months ended June 30, 2023, we had cash provided by investing activities of \$42.0Â million primarily from the sales and maturities of investments.Financing activitiesDuring the six months ended June 30, 2024, we had cash provided by financing activities of \$25.5Â million, consisting of proceeds from the sale of shares of our common stock pursuant to the ATM Program as well as exercises of stock options and participation in the employee stock purchase plan. During the six months ended June 30, 2023, we had cash provided by financing activities of \$0.1Â million consisting of proceeds from the participation in the employee stock purchase plan.31Table of ContentsFunding requirementsWe expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance clinical trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. The timing and amount of our operating expenditures will depend largely on our ability to:â€¢advance BDTX-1535 and BDTX-4933 through clinical trials;â€¢manufacture, or have manufactured on our behalf, our drug material and develop processes for late stage and commercial manufacturing;â€¢seek regulatory approvals for any product candidates that successfully complete clinical trials;â€¢establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own;â€¢hire additional clinical, quality control and scientific personnel; andâ€¢obtain, maintain, expand, enforce and protect our intellectual property portfolio.As of June 30, 2024, we had cash, cash equivalents and investments of \$123.0 million. We believe that our existing cash, cash equivalents and investments will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize.Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to further reduce or terminate our operations. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:â€¢the scope, progress, results and costs of developing our product candidates, and conducting clinical trials;â€¢the costs, timing and outcome of regulatory review of our product candidates;â€¢the costs, timing and ability to manufacture our product candidates to supply our clinical development efforts and our clinical trials;â€¢the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;â€¢subject to receipt of regulatory approval, the costs of commercialization activities for our product candidates, to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities; â€¢the ability to receive additional non-dilutive funding;â€¢the revenue, if any, received from commercial sale of our product candidates, should any of our product candidates receive marketing approval;â€¢the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims;â€¢our ability to establish and maintain collaborations on favorable terms, if at all;â€¢the extent to which we acquire or in-license other product candidates and technologies; and32Table of Contentsâ€¢the costs of operating as a public company.As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time, if ever, as we can generate substantial product revenue from product sales, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties or through other sources of financing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. However, the trading prices for our common stock and for other biopharmaceutical companies have been highly volatile. As a result, we may face difficulties raising capital through sales of our common stock, and such sales may be on unfavorable terms. Similarly, adverse macroeconomic conditions and market volatility resulting from global economic developments, political unrest, high inflation, global health crises, or other factors could materially and adversely affect our ability to consummate an equity or debt financing on favorable terms or at all. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. To the extent that we raise additional capital through the sale of private or public equity or convertible debt securities, the ownership interest of our stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. In addition, debt financing may involve significant cash payment obligations and specific financial ratios that may restrict our ability to operate our business would result in fixed payment obligations.If we raise additional funds through collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, obtain capital through arrangements with collaborators on terms unfavorable to us or pursue merger or acquisition strategies, all of which could adversely affect the holdings or the rights of our stockholders.Contractual obligations and commitmentsThe following summarizes our contractual obligations as of June 30, 2024:Payments Due by PeriodLess than 1 Year1 to 3 Years3 to 5 YearsMore than 5 YearsTotal(in thousands)Property leases - commenced\$4,418Â \$9,199Â \$9,049Â \$5,583Â \$28,249Â Total\$4,418Â \$9,199Â \$9,049Â \$5,583Â \$28,249Â Property leases â€œ commencedThe amounts reported for property leases represent future minimum lease payments under non-cancelable operating leases in effect as of June 30, 2024. The minimum lease payments do not include common area maintenance charges or real estate taxes.33Table of ContentsOther contractual obligationsThe contractual obligations table does not include any potential future milestone payments or royalty payments we may be required to make under our existing license agreements due to the uncertainty of the occurrence of the events requiring payment under those agreements.Critical accounting policies and significant judgments and use of estimatesOur condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies are described under the heading â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ Critical Accounting Policies and Use of Estimatesâ€ in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 12, 2024. During the six months ended June 30, 2024, there were no material changes to our critical accounting policies from those previously disclosed.Recently issued accounting pronouncementsA description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.Emerging growth company and smaller reporting company status The Jumpstart Our Business Startups Act of 2012 (the JOBS Act) permits an â€œemerging growth companyâ€ such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to not â€œopt outâ€ of this provision and, as a result, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to â€œopt outâ€ of such extended transition period or (ii) no longer qualify as an emerging growth company. We are also a â€œsmaller reporting companyâ€ meaning that the market value of our stock held by non-affiliates is less than \$700 million and our annual revenue was less than \$100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than \$250 million or (ii) our annual revenue was less than \$100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than

[illegible]

Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - BENEFIT PLANS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bdtx-20240630 cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 bdtx-20240630 def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 bdtx-20240630 lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Impairment of fair value assets Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded Lessee, Operating Lease, Liability, to be Paid [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Options vested or expected to vest, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Maximum employee subscription rate Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Adjustment to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Lease Cost and Other Operating Lease Information Lease, Cost [Table Text Block] Cover [Abstract] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] ATM Program At Market Equity Program [Member] At Market Equity Program Trading Symbol(s) Trading Symbol Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Computation of Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Sale of stock, authorized consideration Sale of Stock, Authorized Consideration Sale of Stock, Authorized Consideration Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Equity method investment Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Area leased (square feet) Lessee, Operating Lease, Area Lessee, Operating Lease, Area Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount LEASES Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Lease Cost Lease, Cost [Abstract] Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Plan Name [Domain] Plan Name [Domain] Stock price (in dollars per share) Sale of Stock, Price Per Share Proceeds from equity financing Proceeds from Issuance or Sale of Equity Other non-current assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] (Accretion) amortization on investments Investment Income, Net, Amortization of Discount and Premium Corporate bonds Corporate bonds Corporate Bond Securities [Member] Money market funds Money Market Funds [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Sale of stock, net of offering costs Sale of Stock, Consideration Received on Transaction Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Noncash rent expense Rent Expense Rent Expense Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value Debt Securities, Available-for-Sale 2020 Stock Option Plan 2020 Stock Option Plan [Member] 2020 Stock Option Plan Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Options outstanding, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] LevelA 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Shelf Registration Statement Shelf Registration Statement [Member] Shelf Registration Statement Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Issuance of common stock related to ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities, Current Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount BENEFIT PLANS Compensation and Employee Benefit Plans [Text Block] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Increase of authorized shares, percent of common stock outstanding Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding Current assets: Assets, Current [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Short-term lease cost Short-Term Lease, Cost Stock options Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Depreciation expense Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Warrants to purchase common stock Warrant [Member] Name of each exchange on which registered Security Exchange Name Award Type [Axis] Award Type [Axis] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Lease Contractual Term [Domain] Lease Contractual Term [Domain] NumberA of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Total Property and Equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Current portion of operating lease liability Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment Property, Plant and Equipment, Gross Exercise of common stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development Expense [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Commercial paper Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Principles of consolidation and unaudited interim financial information Basis of Accounting, Policy [Policy Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Lease term, optional extension (in years) Lessee, Operating Lease, Renewal Term Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Elizabeth Buck [Member] Elizabeth Buck PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Letter of credit outstanding Letters of Credit Outstanding, Amount Recurring Fair Value, Recurring [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Employer contribution, matching contribution percentage Defined Contribution Plan, Employer Matching Contribution, Percent of Match Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Options outstanding, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Options exercisable, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Other income (expense): Other Income and Expenses [Abstract] Units vested (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Four Lessee, Operating Lease, Liability, Payments, Due after Year Four Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Furniture and fixtures Furniture and Fixtures [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Contracted research services Accrued Contract Research Service Fees, Current Accrued Contract Research Service Fees, Current Leasehold improvements Leasehold Improvements [Member] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Current Fiscal Year End Date Current Fiscal Year End Date Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease cost Lease, Cost 2020 ESPP 2020 Employee Stock Purchase Plan [Member] 2020 Employee Stock Purchase Plan PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Shares issued under share-based compensation plan Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Stock-based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Variable lease cost Variable Lease, Cost Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] (Gain) Loss on sale of equipment Gain (Loss) on Sale of Equipment Gain (Loss) on Sale of Equipment Investments: Investments, Fair Value Disclosure Additional paid-in capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Investment, Name [Axis] Investment, Name [Axis] Restricted cash Restricted cash, end of period Restricted Cash, Noncurrent Recently issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Net loss per share, diluted (in dollars per share) Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Retirement Benefits [Abstract] Employer contribution, percent of each participant's salary Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Statement of Financial Position [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Fair value of units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Proceeds from sale of equipment Proceeds from Sale of Property, Plant, and Equipment Investments Debt Securities, Available-for-Sale, Current Non-current operating lease liabilities Increase (Decrease) in Operating Lease Liabilities Increase (Decrease) in Operating Lease Liabilities Unrecognized compensation cost, recognition period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total other income (expense), net Nonoperating Income (Expense) Statement of Comprehensive Income [Abstract] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Total liabilities and stockholders' equity Liabilities and Equity All Adjustments to Compensation All Adjustments to Compensation [Member] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Payroll and related expenses Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Commitments and Contingencies Disclosure [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Surrender of shares for taxes Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Cancelled or forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Principal office, lease two Operating Lease, Principal Office, Two [Member] Operating Lease, Principal Office, Two Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Sublease income Sublease Income Unvested restricted common stock, beginning balance (in dollars per share) Unvested restricted common stock, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Restatement Determination Date Restatement Determination Date Options vested or expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Adoption Date Trading Arrangement Adoption Date Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding, beginning balance (in shares) Outstanding, ending

balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Property, Plant and Equipment [Abstract] Exercise Price Award Exercise Price Lease Contractual Term [Axis] Lease Contractual Term [Axis] NET LOSS PER SHARE Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Issuance of common stock related to ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Exercise of common stock options Stock Issued During Period, Value, Stock Options Exercised Stockholders' equity: Equity, Attributable to Parent [Abstract] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Accounts payable Increase (Decrease) in Accounts Payable, Trade All Individuals [Member] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] PEO PEO [Member] Revelio Therapeutics Revelio Therapeutics [Member] Revelio Therapeutics Name Trading Arrangement, Individual Name Other income (expense) Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Other non-current assets Increase (Decrease) in Other Noncurrent Assets Proceeds from exercise of common stock options and ESPP Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Assets: Assets, Fair Value Disclosure [Abstract] Interest income Investment Income, Nonoperating Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Schedule of Equity Method Investments [Table] Equity Method Investment [Table] Weighted Average Remaining Life and Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in current assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Maximum percent of fair market value of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Entity Ex Transition Period Entity Ex Transition Period Options vested or expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Proceeds from sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Common stock Common Stock [Member] Measure: Measure [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Surrender of shares for taxes (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Entity Central Index Key Entity Central Index Key General and administrative General and Administrative Expense [Member] Equity Method Investments and Joint Ventures [Abstract] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Schedule of Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Unvested restricted stock Restricted Stock [Member] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Measurement Frequency [Domain] Measurement Frequency [Domain] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Follow-on Offering Follow-on Offering [Member] Follow-on Offering Weighted average grantA date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings Per Share [Abstract] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total lease liability Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Unvested performance restricted stock units Performance Shares [Member] INVESTMENTS Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Fair Value as of Grant Date Award Grant Date Fair Value Options vested or expected to vest, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Level 2 Fair Value, Inputs, Level 2 [Member] Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Issuance of common stock, net of issuance costs Sale of stock, gross Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Principles of consolidation Consolidation, Policy [Policy Text Block] Number of leases Lessee, Operating Lease, Number Of Contracts Lessee, Operating Lease, Number Of Contracts Restatement Determination Date: Restatement Determination Date [Axis] Title of each class Title of 12(b) Security Common stock; \$0.0001 par value; 500,000,000 shares authorized at JuneA 30, 2024 and DecemberA 31, 2023; 56,408,487 shares issued and outstanding at JuneA 30, 2024 and 51,645,557 shares issued and outstanding at DecemberA 31, 2023 Common Stock, Value, Issued Award purchase period (in months) Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and cash equivalents, end of period Cash and Cash Equivalents, at Carrying Value Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Cancelled or forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, \$0.0001 par value; 10,000,000 shares authorized at JuneA 30, 2024 and DecemberA 31, 2023; no shares issued or outstanding at JuneA 30, 2024 and DecemberA 31, 2023 Preferred Stock, Value, Issued Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Shares issuable under employee stock purchase plan Employee Stock [Member] Net loss per share, basic (in dollars per share) Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock Cash paid for amounts included in the measurement of lease liability Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Unrecognized compensation cost, options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Units granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Other Operating Lease Information Lease, Other Information [Abstract] Lease, Other Information [Abstract] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (NoteA 11) Commitments and Contingencies EQUITY METHOD INVESTMENT Equity Method Investments and Joint Ventures Disclosure [Text Block] Performance restricted stock units Performance Restricted Stock Units [Member] Performance Restricted Stock Units Employee Stock Purchase Plan and Other Other Award Type [Member] Other Award Type Termination Date Trading Arrangement Termination Date NATURE OF BUSINESS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Employer contribution amount Defined Contribution Plan, Employer Discretionary Contribution Amount Units forfeited (in shares) Cancelled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Document Fiscal Year Focus Document Fiscal Year Focus Entity Address, Address Line One Entity Address, Address Line One Lease term (in years) Lessee, Operating Lease, Term of Contract Total Assets, Fair Value Disclosure Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Name Forgone Recovery, Individual Name 2024 (excluding the six months ended JuneA 30, 2024) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Options exercisable, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total lease payments Lessee, Operating Lease, Liability, to be Paid Units outstanding (in shares) Unvested restricted common stock, beginning balance (in shares) Unvested restricted common stock, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Insider Trading Arrangements [Line Items] Unrealized gain (loss) on investments, net Unrealized gain (loss) on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Maximum employee subscription amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common shares received from equity method investment (in shares) Equity Method Investment, Shares Received in Noncash Exchange Equity Method Investment, Shares Received in Noncash Exchange Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Restricted stock units Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Professional and consulting fees Accrued Professional Fees, Current Executive Category: Executive Category [Axis] Operating Lease, Office and Laboratory Space, NY Operating Lease, Office and Laboratory Space, NY [Member] Operating Lease, Office and Laboratory Space, NY Purchases of investments Payments to Acquire Investments Name Awards Close in Time to MNPI Disclosures, Individual Name Canceled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 9 bdtx-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover Page - shares 6 Months Ended Jun. 30, 2024 Aug. 01, 2024 Cover [Abstract] A Document Type 10-Q A Document Quarterly Report true A Document Period End Date Jun. 30, 2024 A Document Transition Report false A Entity File Number 001-38501 A Entity Registrant Name BLACK DIAMOND THERAPEUTICS, INC. A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 81-4254660 A Entity Address, Address Line One One Main Street, 14th Floor A Entity Address, City or Town Cambridge A Entity Address, State or Province MA A Entity Address, Postal Zip Code 02142 A City Area Code (617) A Local Phone Number 252-0848 A Title of each class Common stock, par value \$0.0001 A Trading Symbol(s) BDTX A Name of each exchange on which registered NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company true A Entity Ex Transition Period false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 56,504,895 Amendment Flag false A Document Fiscal Period Focus Q2 A Document Fiscal Year Focus 2024 A Entity Central Index Key 0001701541 A Current Fiscal Year End Date -12-31 A X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X -

DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1:

FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 28: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference) 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference) 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference) 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference) 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference) 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference) 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference) 6: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference> 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap AssetsCurrentNamespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference) 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/214779130/326-30-45-1 + Details Name: us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/214779130/326-30-45-1 + Details Name: us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrentNamespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference) 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference) 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214747877/944-210-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/214747877/944-210-S99-1Reference) 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214747877/944-210-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-210-S99-1 + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214747877/944-210-S99-1 + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/214747877/944-210-S99-1 + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference) 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference) 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference) 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference) 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference) 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference) 15:

944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(32\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1) + Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 8: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 21: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7) + Details Name: us-gaap LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7)Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 10 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8> + Details Name: us-gaap RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5:

1Reference 2:

<http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1> + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_InvestmentIncomeNonoperating Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 7: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-10A> + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482916/730-10-50-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479532/912-730-25-1> + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-16> + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10> + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 15 R5.htm IDÉA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$) \$ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities: Á Á Net loss \$ (38,134) \$ (40,027) Adjustment to reconcile net loss to net cash used in operating activities: Á Á Stock-based compensation expense 6,999 5,317 Depreciation expense 172 236 (Accretion) amortization on investments (2,037) 130 Noncash rent expense 1,465 1,388 (Gain) Loss on sale of equipment (38) 37 Changes in current assets and liabilities: Á Á Prepaid expenses and other current assets (1,149) 1,434 Other non-current assets (337) 0 Accounts payable (1,561) 826 Accrued expenses and other current liabilities 354 (2,223) Non-current operating lease liabilities (1,659) (1,517) Net cash used in operating activities (33,925) (34,399) Cash flows from investing activities: Á Á Proceeds from sale of equipment 38 95 Proceeds from sales and maturities of investments 79,000 41,886 Purchases of investments (92,032) 0 Net cash (used in) provided by investing activities (12,994) 41,981 Cash flows from financing activities: Á Á Proceeds from exercise of common stock options and ESPP 514 51 Proceeds from issuance of common stock, net of issuance costs 24,994 0 Net cash provided by financing activities 25,508 51 Net (decrease) increase in cash and cash equivalents (23,411) 7,633 Cash, cash equivalents and restricted cash, beginning of period 57,044 35,483 Cash, cash equivalents and restricted cash, end of period 33,633 43,116 Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Á Á Cash and cash equivalents, end of period 32,811 41,888 Restricted cash, end of period 82 1,228 Cash, cash equivalents and restricted cash, end of period \$ 33,633 \$ 43,116 X - DefinitionGain (Loss) on Sale of Equipment + ReferencesNo definition available. + Details Name: bdtx_GainLossOnSaleOfEquipment Namespace Prefix: bdtx_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionIncrease (Decrease) in Operating Lease Liabilities + ReferencesNo definition available. + Details Name: bdtx_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: bdtx_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionRent Expense +

ReferencesNo definition available. + Details Name: us-gaap bdtx RentExpense Namespace Prefix: bdtx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4>

+ Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4>

+ Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1)

+ Details Name: us-gaap Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.

+ ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details Name: us-gaap IncreaseDecreaseInAccountsPayableTrade Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other.

+ ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details Name: us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other.

+ ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details Name: us-gaap IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other.

+ ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details Name: us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accretion (amortization) of purchase discount (premium) on nonoperating securities.

+ ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)

+ Details Name: us-gaap InvestmentIncomeNetAmortizationOfDiscountAndPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>

+ Details Name: us-gaap NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>

+ Details Name: us-gaap NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>

+ Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)

Details Name: us-gAAP_PaymentsToAcquireEstimatesNameSpace Prefix: us-gAAP_Data Type: xBRL:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gAAP/role/ref/legacyRef -Name Accounting Standards Codification -Section 45-Paragraph 14 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gAAP_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gAAP_Data Type: xBRL:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gAAP/role/ref/legacyRef -Name Accounting Standards Codification -Section 45-Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gAAP/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gAAP_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gAAP_Data Type: xBRL:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gAAP_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gAAP_Data Type: xBRL:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-IReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/214747220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gAAP_RestrictedCashNoncurrent Namespace Prefix: us-gAAP_Data Type: xBRL:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gAAP/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gAAP_ShareBasedCompensation Namespace Prefix: us-gAAP_Data Type: xBRL:monetaryItemType Balance Type: debit Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD (\$) in Thousands Total Common stock Additional paid-in capital Accumulated other comprehensive income (loss) Accumulated deficit Beginning balance (in shares) at Dec. 31, 2022 \$ 36,434,297 \$ A A Beginning balance at Dec. 31, 2022 \$ 115,695 \$ 5 \$ 452,503 \$(1,824) \$(334,989) Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A Vesting of restricted stock units (in shares) A 23,575 A A Surrender of shares for taxes (in shares) A (3,903) A A Issuance of common stock related to ESPP (in shares) A 33,202 A A Issuance of common stock related to ESPP 51 A 51 A Stock-based compensation (in shares) A 24,776 A A Stock-based compensation 2,671 A 2,671 A Unrealized gain (loss) on investments 648 A 648 A Net loss (20,875) A A (20,875) Ending balance (in shares) at Mar. 31, 2023 36,511,947 A A Ending balance at Mar. 31, 2023 98,190 \$ 5 455,225 (1,176) (355,864) Beginning balance (in shares) at Dec. 31, 2022 \$ 36,434,297 A A Beginning balance at Dec. 31, 2022 \$ 115,695 \$ 5 452,503 (1,824) (334,989) Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A Unrealized gain (loss) on investments 1,163 A A A Net loss (40,027) A A A Ending balance (in shares) at Jun. 30, 2023 36,533,525 A A A Ending balance at Jun. 30, 2023 82,199 \$ 5 457,871 (661) (375,016) Beginning balance (in shares) at Mar. 31, 2023 36,511,947 A A Beginning balance at Mar. 31, 2023 98,190 \$ 5 455,225 (1,176) (355,864) Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A Vesting of restricted stock units (in shares) A 1,875 A A Stock-based compensation (in shares) A 19,703 A A Stock-based compensation 2,646 A 2,646 A Unrealized gain (loss) on investments 515 A 515 A Net loss (19,152) A A (19,152) Ending balance (in shares) at Jun. 30, 2023 36,533,525 A A A Ending balance at Jun. 30, 2023 82,199 \$ 5 457,871 (661) (375,016) Beginning balance (in shares) at Dec. 31, 2023 51,645,557 51,645,557 A A Beginning balance at Dec. 31, 2023 \$ 116,736 \$ 7 534,187 (27) (417,431) Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A Issuance of common stock, net of issuance costs (in shares) A 800,000 A A A Issuance of common stock, net of issuance costs 4,000 A 4,000 A Exercise of common stock options (in shares) A 47,741 A A A Exercise of common stock options 86 A 86 A Vesting of restricted stock units (in shares) A 1,250 A A A Issuance of common stock related to ESPP (in shares) A 26,659 A A A Issuance of common stock related to ESPP 64 A 64 A Stock-based compensation (in shares) A 6,419 A A A Stock-based compensation 1,713 A 1,713 A Unrealized gain (loss) on investments (68) A (68) A Net loss (18,225) A A (18,225) Ending balance (in shares) at Mar. 31, 2024 52,527,626 A A A Ending balance at Mar. 31, 2024 \$ 104,306 \$ 7 540,050 (95) (435,656) Beginning balance (in shares) at Dec. 31, 2023 51,645,557 51,645,557 A A Beginning balance at Dec. 31, 2023 \$ 116,736 \$ 7 534,187 (27) (417,431) Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A Exercise of common stock options (in shares) A 216,713 A A A Unrealized gain (loss) on investments (88) A A A Net loss (\$38,134) A A A Ending balance (in shares) at Jun. 30, 2024 56,408,487 56,408,487 A A A Ending balance at Jun. 30, 2024 \$ 111,021 \$ 7 566,694 (115) (455,565) Beginning balance (in shares) at Mar. 31, 2024 52,527,626 A A A Beginning balance at Mar. 31, 2024 \$ 104,306 \$ 7 540,050 (95) (435,656) Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A Issuance of common stock, net of issuance costs (in shares) A 3,690,853 A A A Issuance of common stock, net of issuance costs 20,994 A 20,994 A Exercise of common stock options (in shares) A 168,972 A A A Exercise of common stock options 389 A 389 A Vesting of restricted stock units (in shares) A 18,199 A A A Surrender of shares for taxes (in shares) A (4,696) A A A Surrender of shares for taxes (25) A (25) A A Stock-based compensation (in shares) A 7,533 A A A Stock-based compensation 5,286 A 5,286 A Unrealized gain (loss) on investments (20) A (20) A Net loss (\$19,909) A A (19,909) Ending balance (in shares) at Jun. 30, 2024 56,408,487 56,408,487 A A A Ending balance at Jun. 30, 2024 \$ 111,021 \$ 7 566,694 (115) (455,565) X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gAAP_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensationNamespace Prefix: us-gAAP_Data Type: xBRL:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gAAP/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gAAP/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gAAP_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gAAP_Data Type: xBRL:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gAAP/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gAAP/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-IReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPractice

-Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference> 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference> 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-10A> + Details Name: us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference> 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference> 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference> 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference> 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference> 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.2.1a1 NATURE OF BUSINESS AND BASIS OF PRESENTATION 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] A NATURE OF BUSINESS AND BASIS OF PRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATIONBlack Diamond Therapeutics, Inc. (the Company) is a clinical-stage oncology company developing MasterKey Therapies that target families of oncogenic mutations in patients with cancer. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development and advancement of its product candidates identified by its Mutation-Allostery-Pharmacology (MAP) drug discovery engine. The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry. There can be no assurance that the Company's research and development will be successfully completed, that adequate protection for the Company's technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company's product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company's common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of \$500 million. The Company simultaneously entered into an Open Market Sale AgreementSM with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to \$150 million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of June 30, 2024, the Company sold 4,490,853 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately \$25.0 million (\$24.5 million net of offering costs). On July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company's common stock at a price to the public of \$5.00 per share. The aggregate net proceeds from the Follow-on Offering

totalled approximately \$71.9 million, after deducting underwriting discounts and commissions. The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of common stock and preferred stock. The Company has had recurring losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of \$455.6 million as of June 30, 2024. The Company expects to continue to generate operating losses for the foreseeable future. As of August 6, 2024, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these condensed consolidated financial statements. The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent> + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT V3.24.2.1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] A SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution.Unaudited interim financial informationThe condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of the Company's management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.Use of estimates The preparation of the Company's condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. The Company continues to monitor the impact of global economic developments, political unrest, high inflation, disruptions in capital markets, changes in international trade relationships and military conflicts, and health crises, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company's business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates.Recently issued accounting pronouncementsIn December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company's consolidated financial statements.In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280) (ASU 2023-07) which requires enhanced disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entity's CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. The amendments also expand the interim segment disclosure requirements. This new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this ASU apply retrospectively to all prior periods presented in the financial statements. The Company is in the process of assessing the impact on its financial statements from the adoption of the new guidance and the period in which the new guidance will be adopted.In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements - Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative (ASU 2023-06). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company's consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent> + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT V3.24.2.1 FAIR VALUE MEASUREMENTS 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] A FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTSThe following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: Fair value measurements at June 30, 2024 using:Level 1Level 2Level 3TotalAssets:Cash equivalents:Money market funds\$31,821A \$6A \$6A \$31,821A Investments:Commercial paperA \$74,395A \$6A \$74,395A Corporate bondsA \$15,765A \$6A \$15,765A Total\$31,821A \$90,160A \$6A \$121,981A Fair value measurements at December 31, 2023 using:Level 1Level 2Level 3TotalAssets:Cash equivalents:Money market funds\$30,803A \$6A \$6A \$30,803A Investments:Commercial paperA \$44,871A \$6A \$44,871A Corporate bondsA \$30,308A \$6A \$30,308A Total\$30,803A \$75,179A \$6A \$105,982A When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. There were no transfers in or out of Level 3 categories in the periods presented. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1) + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT V3.24.2.1 INVESTMENTS 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] A INVESTMENTS INVESTMENTSA of June 30, 2024, investments were comprised of the following:Amortized CostUnrealized GainsUnrealized LossesFair ValueCommercial paper\$74,489A \$6A \$74,489A Corporate bonds\$15,786A \$6A \$15,786A Total\$90,275A \$6A \$90,275A As of December 31, 2023, investments were comprised of the following:Amortized CostUnrealized GainsUnrealized LossesFair ValueCommercial paper\$44,880A \$4A \$13\$44,871A Corporate bonds\$30,326A \$6A \$30,308A Total\$75,206A \$4A \$75,179A As of June 30, 2024, all marketable securities held by the Company had remaining contractual maturities of one year or less.As of December 31, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less.As of June 30, 2024, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments. The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss. There have been no impairments of the Company's assets measured and carried at fair value during the six months ended June 30, 2024 and the year ended December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContent>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Name Regulation S-K \(SK\) -Number 229 -Section 1403 -Paragraph b -Publisher SEC](http://www.xbrl.org/2003/role/disclosureRef-Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SEC)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10](http://www.xbrl.org/2003/role/disclosureRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6)Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent> + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT V3.24.2.1 PROPERTY AND EQUIPMENT 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] A PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENTProperty and equipment, net consisted of the following:June 30,2024December 31,2023Furniture and fixtures17A \$17A Leasehold improvements2,512A 2,512A Property and equipment2,529A 2,529A Less: accumulated depreciation(971)(799)Total Property and Equipment, net\$1,558A \$1,730A Depreciation expense for the

six months ended June 30, 2024, 2023 and 2023 was \$172 and \$236, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2>:

follows: As of June 30, 2024/2024 (excluding the six months ended June 30, 2024)\$2,199.4 2025/4,477.4 2026/4,599.4 2027/4,724.4 2028/3,926.4 Thereafter/8,324.4 Total lease payments28,249.4 Less: interest/(4,467)Total lease liabilities\$23,782.4 X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1:

<http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-K-Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd TrdArrIndName Namespace Prefix: ecd Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-K-Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd TrdArrIndTitle Namespace Prefix: ecd Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-K-Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd IndividualAxis=bdtx ElizabethBuckMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Principles of consolidation and unaudited interim financial information Black Diamond Therapeutics, Inc. (the Company) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development and advancement of its product candidates identified by its Mutation-Allostery-Pharmacology (MAP) drug discovery engine. The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry. There can be no assurance that the Companyâ€™s research and development will be successfully completed, that adequate protection for the Companyâ€™s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Companyâ€™s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution. Unaudited interim financial information The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of the Companyâ€™s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included. Principles of consolidation Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution. Use of estimates Use of estimates The preparation of the Companyâ€™s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Recently issued accounting pronouncements Recently issued accounting pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Companyâ€™s consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280) (ASU 2023-07) which requires enhanced disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entityâ€™s CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. The amendments also expand the interim segment disclosure requirements. This new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this ASU apply retrospectively to all prior periods presented in the financial statements. The Company is in the process of assessing the impact on its financial statements from the adoption of the new guidance and the period in which the new guidance will be adopted. In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements - Codification Amendments in Response to the SECâ€™s Disclosure Update and Simplification Initiative (ASU 2023-06). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Companyâ€™s consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483426/235-10-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1> + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-9>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-4>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-12>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-8> + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE MEASUREMENTS (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis The following tables present information about the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: Fair value measurements at June 30, 2024 using:Level 1Level 2Level 3TotalAssets:Cash equivalents:Money market funds\$31,821A \$â€”A \$â€”A \$31,821A Investments:Commercial paperâ€”A 74,395A â€”A 74,395A Corporate bondsâ€”A 15,765A â€”A 15,765A Total\$31,821A \$90,160A \$â€”A \$121,981A Fair value measurements at December 31, 2023 using:Level 1Level 2Level 3TotalAssets:Cash equivalents:Money market funds\$30,803A \$â€”A \$â€”A \$30,803A Investments:Commercial paperâ€”A 44,871A â€”A 44,871A Corporate bondsâ€”A 30,308A â€”A 30,308A Total\$30,803A \$75,179A \$â€”A \$105,982A X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap_ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 INVESTMENTS (Tables) 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Schedule of Marketable Securities As of June 30, 2024, investments were comprised of the following:Amortized CostUnrealized GainsUnrealized LossesFair ValueCommercial papers\$74,489A \$â€”A \$(94)\$74,395A Corporate bonds15,786A â€”A (21)15,765A Total\$90,275A \$â€”A \$(115)\$89,160A As of December 31, 2023, investments were comprised of the following:Amortized CostUnrealized GainsUnrealized LossesFair ValueCommercial paper\$44,880A \$â€”A \$(13)\$44,871A Corporate bonds30,326A â€”A (18)30,308A Total\$75,206A \$4A \$(31)\$75,179A X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-9>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 9: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-3> + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 PROPERTY AND EQUIPMENT (Tables) 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] Â Schedule of Property, Plant and Equipment Property and equipment, net consisted of the following:June 30,2024December 31,2023Furniture and fixtures\$17A \$17A Leasehold improvements2,512A 2,512A Property and equipment2,529A 2,529A Less: accumulated depreciation(971)(799)Total Property and Equipment, net\$1,558A \$1,730A X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] Â Schedule of Accrued Expenses Accrued expenses and other current liabilities consisted of the following:June 30,2024December 31,2023Contracted research services\$9,986A \$8,071A Payroll and related expenses3,489A 5,175A Professional and consulting fees945A 963A Current portion of operating lease liability3,256A 3,113A Total accrued expenses and other current liabilities\$17,676A \$17,322A X - ReferencesNo definition available. + Details Name: us-

gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemBalance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] A Schedule of Stock-Based Compensation The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Stock options\$5,204Â \$2,475Â \$6,827Â \$4,930Â Restricted stock units2A 80A 18A 191A Employee Stock Purchase Plan and Other80A 91A 154A 196A \$5,286A \$2,464A \$6,999A \$5,317A The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Research and developments733A \$833A \$1,368A \$1,782A General and administrative4,553A 1,813A 5,631A 5,355A \$5,286A \$2,464A \$6,999A \$5,317A Schedule of Stock Option Activity The following table summarizes the stock option activity under the Company's equity awards plans:OptionsWeightedAverageExercisePriceWeightedAverageRemainingLife(in Years)IntrinsicValue(in thousands)Outstanding December 31, 20238,135,711A \$7.85A 8.0\$1,146A Granted3,604,552A \$4.95A Exercised(216,713)\$2.19A Cancelled or forfeited(115,824)\$4.21A Expired(38,098)\$22.04A Outstanding June 30, 202411,369,628A \$7.02A 8.1\$9,170A Options vested or expected to vest at June 30, 202411,369,628A \$7.02A 8.1\$9,170A Options exercisable at June 30, 20244,259,001A \$11.21A 6.5\$3,344A Schedule of Restricted Stock Activity The following table summarizes time-based restricted stock activity since January 1, 2024:NumberA ofsharesWeightedaveragegrantA datefair valueUnvested restricted common stock as of December 31, 202320,799A \$2.41A Vested(19,449)\$2.40A Cancelled or forfeited(1,350)\$2.55A Unvested restricted common stock as of June 30, 202446A \$A \$A X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock shares. + ReferencesReference 1:

Topic 820 - SubTopic 10 - Name Accounting Standards Codification - Section 55 - Paragraph 100 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2:

1, 2023 Dec. 31, 2022 Schedule of Equity Method Investments [Line Items] A A A Common shares received from equity method investment (in shares) A A 9,000.00 Equity method investment, ownership percentage 21.20% 39.10% A Equity method investment \$ 0 \$ 0 A - DefinitionEquity Method Investment, Shares Received in Noncash Exchange + ReferencesNo definition available. + Details Name: bdtx EquityMethodInvestmentSharesReceivedInNoncashExchange Namespace Prefix: bdtx Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3) + Details Name: us-gaap EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap Data Type: dtr:percentItem Type Balance Type: na Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147481664/323-10-45-1>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(10\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(10))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 25-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 25-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25) + Details Name: us-gaap EquityMethodInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(a\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (a)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3) + Details Name: us-gaap ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: srt.ScheduleOfEquityMethodInvestmentEquityMethodInvestmentItemAxis=bdtx.ReveloTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD (\$) \$ in Thousands Jun. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] A A Contracted research services \$ 9,986 \$ 8,071 Payroll and related expenses 3,489 5,175 Professional and consulting fees 945 963 Current portion of operating lease liability \$ 3,256 \$ 3,113 Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total accrued expenses and other current liabilities Total accrued expenses and other current liabilities Total accrued expenses and other current liabilities \$ 17,676 \$ 17,322 X - DefinitionAccrued Contract Research Service Fees, Current + ReferencesNo definition available. + Details Name: bdtx AccruedContractResearchServiceFeesCurrent Namespace Prefix: bdtx Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect

[https://asc.fasb.org/1943274/2147480483/718-10-50-Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(vi\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(vii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(viii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](#)

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineltms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](#) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Balance Type: na Period Type: instant X - Definition Number of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Balance Type: na Period Type: duration X - Definition Number of shares issued under share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](#) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Balance Type: na Period Type: duration X - Definition Purchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=bdtx_PerformanceRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bdtx_A2020StockOptionPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=bdtx_A2020EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense \$ 5,286 \$ 2,646 \$ 6,999 \$ 5,137 Research and development A A A Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense 733 833 1,368 General and administrative A A A Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense 4,553 1,813 5,631 3,535 Stock options A A A Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense 5,204 2,475 6,827 4,930 Restricted stock units A A A Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense 2 80 191 Employee Stock Purchase Plan and Other A A A Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense \$ 80 \$ 91 \$ 154 \$ 196 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 14.F\) -Publisher FASB -URI https://asc.fasb.org](#)

performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemtype Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) \(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) (iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) \(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) (iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) \(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) (iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) \(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) (iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details> Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtNnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details> Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtNnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph \(e\)\(1\) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDtNnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemtype Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) \(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) (iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details) Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemtype Balance Type: na Period Type: duration XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) - Unvested restricted stock 6 Months Ended Jun. 30, 2024 \$ / shares shares NumberÅ of shares Å Unvested restricted common stock, beginning balance (in shares) | shares 20,799 Vested (in shares) | shares (19,449) Cancelled or forfeited (in shares) | shares (1,350) Unvested restricted common stock, ending balance (in shares) | shares 0 Weighted average grantÅ date fair value Å Unvested restricted common stock, beginning balance (in dollars per share) | \$ / shares \$ 2.41 Vested (in dollars per share) | \$ / shares 2.40 Cancelled or forfeited (in dollars per share) | \$ / shares 2.55 Unvested restricted common stock, ending balance (in dollars per share) | \$ / shares \$ 0 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\) \(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) (iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\) \(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) (iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\) \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\) \(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) (ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemtype Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemtype Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\) \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\) \(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) (ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemtype Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\) \(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) (iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 NET LOSS PER SHARE - Computation of Net Loss per Share (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Earnings Per Share [Abstract] Å Å Å Å Å Net loss \$ (19,909) \$ (18,225) \$ (19,152) \$ (20,875) \$ (38,134) \$ (40,027) Weighted average common shares outstanding, basic (in shares) 55,155,220 Å 36,516,114 Å 53,482,034 36,500,085 Weighted average common shares outstanding, diluted (in shares) 55,155,220 Å 36,516,114 Å 53,482,034 36,500,085 Net loss per share, basic (in dollars per share) \$ (0.36) Å \$ (0.52) Å \$ (0.71) \$ (1.09) Net loss per share, diluted (in dollars per share) \$ (0.36) Å \$ (0.52) Å \$ (0.71) \$ (1.09) X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemtype Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1:

Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 LEASES - Narrative (Details) \$ in Thousands 6 Months Ended Jun. 30, 2024 contract Aug. 31, 2023

USD (\$) Dec. 31, 2020 ft² Jul. 31, 2020 USD (\$) ft² Lessee, Lease, Description [Line Items] Á Á Á Number of leases | contract 2 Á Á Á Principal office, lease two Á Á Á Lessee, Lease, Description [Line Items] Á Á Á Lease term (in years) Á Á Á 7 years Lease term, optional extension (in years) Á Á Á 5 years Area leased (square feet) Á Á Á 25,578 Letter of credit outstanding | \$ Á Á 779 Á Á 1,168 Operating Lease, Office and Laboratory Space, NY Á Á Á Lessee, Lease, Description [Line Items] Á Á Á Lease term (in years) Á Á Á 11 years Á Lease term, optional extension (in years) Á Á Á 5 years Á Area leased (square feet) Á Á 18,120 Á X - DefinitionLessee, Operating Lease, Area + ReferencesNo definition available. + Details Name: bdtx_LesseeOperatingLeaseArea Namespace Prefix: bdtx_Data Type: dtr-types:1:areaItemType Balance Type: na Period Type: instant X - DefinitionLessee, Operating Lease, Number Of Contracts + ReferencesNo definition available. + Details Name: bdtx_LesseeOperatingLeaseNumberOfContracts Namespace Prefix: bdtx_Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionThe total amount of the contingent obligation under letters of credit outstanding as of the reporting date. + ReferencesNo definition available. + Details Name: us-gaap_LettersOfCreditOutstandingAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Lease Cost Á Á Á Operating lease cost \$ 1,054 \$ 1,054 \$ 2,108 \$ 2,108 Short-term lease cost 16 11 33 28 Variable lease cost 202 126 439 382 Sublease income (615) (335) (1,071) (470) Total lease cost \$ 657 \$ 856 1,509 2,048 Other Operating Lease Information Á Á Á Cash paid for amounts included in the measurement of lease liability Á Á \$ 2,160 \$ 2,103 Weighted-average remaining lease term (in years) 6 years 4 months 24 days 7 years 4 months 24 days 6 years 4 months 24 days 7 years 4 months 24 days Weighted-average discount rate 5.30% 5.30% 5.30% 5.30% X - DefinitionLease, Other Information [Abstract] + ReferencesNo definition available. + Details Name: bdtx_LeaseOtherInformationAbstract Namespace Prefix: bdtx_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeaseCostAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 LEASES - Schedule of Future Minimum Lease Payments (Details) \$ in Thousands Jun. 30, 2024 USD (\$) Lessee, Operating Lease, Liability, to be Paid [Abstract] Á 2024 (excluding the six months ended June Á 30, 2024) \$ 2,199 2025 4,477 2026 4,599 2027 4,724 2028 3,926 Thereafter 8,324 Total lease payments 28,249 Less: interest (4,467) Total lease liability \$ 23,782 X - DefinitionLessee, Operating Lease, Liability, Payments, Due after Year Four + ReferencesNo definition available. + Details Name: bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: bdtx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BENEFIT PLANS (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Retirement Benefits [Abstract] Á Á Á Employer contribution, matching contribution percentage Á Á 100.00% Á Employer contribution, percent of each participant's salary Á Á 6.00% Á Employer contribution amount \$ 152 \$ 167 \$ 500 \$ 543 X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of discretionary contributions made by an employer to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage employer matches of the employee's percentage contribution matched. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration XCEL 56 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial Report.xlsx M4\$!#1!0 ('TXIED4U@0 + 5 0 9[C4]O< /,087P+GAM M; \$V./OL'.1\$ IQO;=IP4)B0-J2L+ (/>QLO&1.WS<D>OCGICVX<:QA&WPIG M?N1?BV&5(C(I(/147BK9.7=)N)=H16-Y=OGDK7A.YNJQ<4&GPZ4A!OWJ=0U(R;UEA 6!M17E1+ P04 M' /J. 99CWS1.X K @ \$0 &108UIR+1+V.O&ULS9+1 M2LOS(P917O)JVV7(J&B~))071!1.2V-U@XD91.VW-ZV1740?P&F GSS M34*4RG@!J#Q) MX33U*5!P.XPNP01+0+.2E~J2V*H@R621A^_1S80RY8-[9]-NIL!/'SI^Y%1?^H.GS[BYBZ:(E)JX M8-DOV]:[MR >X%#BVR]*+ M41B1%G@M MNN0.1.+5)#3(PB=AlA)4!P1 DQEJ&~& +7&3K!/@\$WVWO@C(WXV[JZMOFCU7 MH5A)JW3X\$8:XIQSYG(1/L14;1JEB6W'.7614IEQC?>HU+&+76>17 /V= M/IT3SLV4'P9IA@)S M&L%&QKMUAUC2/K~!F?<-OHACA?FNVB<+& 9Y>PTGIZ(+&+9OVX?H;5,VPLCO=&'U!=\$Y F15 I,C0' MHY19':V\$5F?JH.(H%&D>NSZ> HWELA*4Z?>P T=HWJPJ3V(I M?RYJSZ70N)JH=W-R.J9J3BUO+1FY;Q/NN=-K7~X8U-RSTS0L\$O=)R2~JVE+ZU(CA) MJ+> <X>RPP19R8Z;9WH1TU' 9+=NOC13J2ET.X&D^> VVZG=PZ.)ZBD;D MTUO< /VZ<5FXN(YV02Y?9A7;?>8T=[Y%L1/O)8=QXCR HBH8-8S;# MAWEI(7YAGE<90- !1M.*PD+>W8+>C72P4X&1@+ /@ZJ1 0356 Q68#M?>B M?>R.1+APY=<? /IDN;5FXU;JL=QEM(EYFFH8\$V-KRMYEL<%5<~1C6 R*P MOFHJ)M5.S Y9KF4QZC;RWRT;?>B;B%DXZDU= [=7GFYRN=BJV^!=-W MP6R17 #)1P E.<?>?%U=KFG[VW>Z/L1[2&R<><<41 71 %B.5% 86%S+D4.Z MD 83 >LX=SFWJXPDP6L UC6'ODRWSEPVSK> UfF M&RQ!1![' 8J*@&K&KXZJL Y9P(M'OQ@2) .;L/=X QU*M:160K\$3J+ MIWP@?>9CC0%>B%&MIK&MQMHQ#F 6/J..H68XWX=.%FAHSU8L.BT*TS M0.4 /Y0-/8-1J9:5XQF:8VH^1.CS<_N\ L+&CN'MB[!4\$!#1!0 (M 'TX!EE0!X#~@8 /? 8 >=PO=VJR.W-H965T&UL MM9EK<^ (V%& BH9V.MN9\$&QQ';LES(!)NGOW63.P;.>=?A'V \$JLBHRA' ? M(QML-A4'CV? YDOAV7O3H2(-KH)Y6R.=XQ,BD+V\$Q0; >UE5+K=>XU&!*YXR.J MLD>81MW&D(&3)IW+9B->2.R\^H.&M.Q.(V1 ^>5.OWTF3V>^>1) 5^0>?>QSD M,KD;D!L;VMV[7#AR\$^NE+&[OZ? 6;.FG7'U93R2->7F(5SPY)Q/LB(I(O;FL# M^Y5X; J K?>?Z-CXZJ 1D+& /QOQYMS=(MXG=VWE99&& L'1X\$6G@& >|> M); I@X/CZHWZ?>P-G,7=&?(OJ=5M&5LC'E'X%P) /BON>@ (X:6L)509S^>M)=OLV5.V1MPD5B+>U=>SUUFF@G 3V8QT'N/O'U.S.90LNLH?>C MNWC-7'Y;@JDB<[GAM?Y]/(I>Z>3C>3WG<2^>P.VE<V,7/2+&)%S%>9KLU-YB MX,95_V0J(KJ5K58Y1.)UXX&8\$>>>?%<(K<+¿,3JWBH%53HY7J<< MWH1+7WAZ%&A&1B3AROE[!DQ\$C/W+>V)PW4&F9= /23#1 (.RU8)I3

[illegible]

[illegible]

[illegible]

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999

```

false false R45.htm 9954495 – Disclosure – BENEFIT PLANS (Details) Sheet http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS Details BENEFIT PLANS (Details) Details
http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS 45 false false All Reports Book All Reports bdtx-20240630.htm bdtx-20240630.sxd bdtx-20240630-cal.xml bdtx-
20240630-doc.xml bdtx-20240630-lab.xml bdtx-20240630-pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 63 MetaLinks.json IDEA:
XBRL DOCUMENT ("version": "2.2", "instance": (" bdtx-20240630.htm" . { "nsprefix": "bdtx", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "dts": { "inline": { "local": { " bdtx-
20240630.htm" } }, "schema": { "local": { " bdtx-20240630.sxd" }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.sxd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.sxd",
"http://www.xbrl.org/2003/xl-2003-12-31.sxd", "http://www.xbrl.org/2003/xlink-2003-12-31.sxd", "http://www.xbrl.org/2005/xbrldt-2005.sxd", "http://www.xbrl.org/2006/ref-2006-02-27.sxd",
"http://www.xbrl.org/rr/role/negated-2009-12-16.sxd", "http://www.xbrl.org/rr/role/net-2009-12-16.sxd", "http://www.xbrl.org/rr/role/reference-2009-12-16.sxd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.sxd", "https://www.xbrl.org/dtr/type/2020-01-21/types.sxd", "https://www.xbrl.org/2022-03-31/types.sxd",
"https://xbrl.fasb.org/srt/2024/elts/srt-2024.sxd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.sxd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.sxd", "https://xbrl.fasb.org/us-
gaap/2024/elts/us-gaap-2024.sxd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.sxd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.sxd",
"https://xbrl.sec.gov/country/2024/country-2024.sxd", "https://xbrl.sec.gov/dei/2024/dei-2024.sxd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.sxd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.sxd"} }
", "calculationLink": { "local": { " bdtx-20240630-cal.xml" } }, "definitionLink": { "local": { " bdtx-20240630-def.xml" } }, "labelLink": { "local": { " bdtx-20240630-lab.xml" } } }, "presentationLink": {
"local": { " bdtx-20240630-pre.xml" } } }, "keyStandard": 218, "keyCustom": 12, "axisStandard": 13, "axisCustom": 0, "memberStandard": 21, "hidden": 1, "total": 10,
"http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 4, "http://xbrl.sec.gov/ecd/2024": 1 }, "contextCount": 155, "entityCount": 1, "segmentCount": 36, "elementCount": 442,
"unitCount": 6, "baseEconomics": { "http://fasb.org/us-gaap/2024": 527, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 11 }, "report": { "R1": { "role":
"http://www.blackdiamondtherapeutics.com/role/CoverPage", "longName": "0000001 – Document – Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document",
"subGroupType": "", "menuCat": "Cover", "order": 1, "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name":
"dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first":
true, "unique": true } }, "R2": { "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "9952151 – Statement – Condensed
Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat":
"Statements", "order": 2, "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3,
"ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-
gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": { "span": "td", "tr", "table", "div", "body", "html" },
"reportCount": 1, "baseRef": " bdtx-20240630.htm", "unique": true } }, "R3": { "role":
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "9952152 – Statement – Condensed Consolidated Balance Sheets
(Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType":
"parenthetical", "menuCat": "Statements", "order": 3, "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil":
"false", "lang": "en-US", "decimals": -4, "ancestors": { "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef":
" bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil":
"false", "lang": "en-US", "decimals": -4, "ancestors": { "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef":
" bdtx-20240630.htm", "first": true, "unique": true } }, "R4": { "role":
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "longName": "9952153 – Statement – Condensed
Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
"isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 4, "firstAnchor": { "contextRef": "c-5", "name": "us-
gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1,
"baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": -3, "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R5": { "role":
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "9952154 – Statement – Condensed Consolidated Statements of Cash
Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat":
"Statements", "order": 5, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": { "span": "td",
"tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": -3, "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "unique":
true } }, "R6": { "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "longName": "9952155 – Statement – Condensed
Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType":
"statement", "subGroupType": "", "menuCat": "Statements", "order": 6, "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil":
"false", "lang": "en-US", "decimals": 0, "ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true }, "uniqueAnchor": {
"contextRef": "c-14", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": 0,
"ancestors": { "span": "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "unique": true } }, "R7": { "role":
"http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION", "longName": "9952156 – Disclosure – NATURE OF BUSINESS AND BASIS OF
PRESENTATION", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order":
7, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {
"span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1,
"baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
"longName": "9952157 – Disclosure – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 8, "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" },
"reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" },
"reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS", "longName":
"9952158 – Disclosure – FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": 9, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {
"span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-
20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS", "longName": "9952159 – Disclosure – INVESTMENTS",
"shortName": "INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 10, "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span":
"div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span":
"div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R11": { "role":
"http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT", "longName": "9952160 – Disclosure – PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND
EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 11, "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1,
"baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R12": { "role":
"http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT", "longName": "9952161 – Disclosure – EQUITY METHOD INVESTMENT", "shortName": "EQUITY METHOD
INVESTMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 12, "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef":
" bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R13": { "role":
"http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES", "longName": "9952162 – Disclosure – ACCRUED EXPENSES AND OTHER CURRENT
LIABILITIES", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order":
13, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name":
"us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div",
"body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R14": { "role":
"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION", "longName": "9952163 – Disclosure – STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED
COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 14, "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" },
"reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" },
"reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE", "longName":
"9952164 – Disclosure – NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 15,
"firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "div", "body",
"html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R16": { "role":
"http://www.blackdiamondtherapeutics.com/role/LEASES", "longName": "9952165 – Disclosure – LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": 16, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseesOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name":
"us-gaap:LesseesOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-
20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952166 – Disclosure –
COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes",
"order": 17, "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-
gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1,
"baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS", "longName": "9952167 – Disclosure –
BENEFIT PLANS", "shortName": "BENEFIT PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 18, "firstAnchor": { "contextRef": "c-1",
"name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" },
"reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true } },
"R19": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "9954410 – Disclosure – Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 19, "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": -3, "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation": "div", "body",
"html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName":
"995445 – Disclosure – Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes",
"order": 20, "firstAnchor": { "contextRef": "c-5", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {
"ecd:Rule10b51ArrTrmtdFlag", "ecd:NonRule10b51ArrTrmtdFlag", "span", "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c-5", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {
"ecd:Rule10b51ArrTrmtdFlag", "ecd:NonRule10b51ArrTrmtdFlag", "span", "div", "body", "html" }, "reportCount": 1, "baseRef": " bdtx-20240630.htm", "first": true, "unique": true } }, "R21": {

role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFFSIGNIFICANTACCOUNTINGPOLICIES(Policies)","longName":"","9954471-Disclosure-SUMMARYOFFSIGNIFICANTACCOUNTINGPOLICIES(Policies)","shortName":"","SUMMARYOFFSIGNIFICANTACCOUNTINGPOLICIES(Policies)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","policies","menuCat":"","Policies","order":"","21","firstAnchor":{"contextRef":"","c-1","name":"","us-gaap:BasicOfAccountingPolicyTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-1","name":"","us-gaap:BasicOfAccountingPolicyTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R22":{"role":"","http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables","longName":"","9954472-Disclosure-FAIRVALUEMEASUREMENTS(Tables)","shortName":"","FAIRVALUEMEASUREMENTS(Tables)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","tables","menuCat":"","Tables","order":"","22","firstAnchor":{"contextRef":"","c-1","name":"","us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-1","name":"","us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R23":{"role":"","http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables","longName":"","9954473-Disclosure-INVESTMENTS(Tables)","shortName":"","INVESTMENTS(Tables)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","tables","menuCat":"","Tables","order":"","23","firstAnchor":{"contextRef":"","c-1","name":"","us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-1","name":"","us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R24":{"role":"","http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables","longName":"","9954474-Disclosure-PROPERTYAND-EQUIPMENT(Tables)","shortName":"","PROPERTYAND-EQUIPMENT(Tables)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","tables","menuCat":"","Tables","order":"","24","firstAnchor":{"contextRef":"","c-1","name":"","us-gaap:PropertyPlantAndEquipmentTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-1","name":"","us-gaap:PropertyPlantAndEquipmentTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R25":{"role":"","http://www.blackdiamondtherapeutics.com/role/ACCRUDEXPENSESANDOTHERCURRENTLIABILITIESTables","longName":"","9954475-Disclosure-ACCRUDEXPENSESANDOTHERCURRENTLIABILITIES(Tables)","shortName":"","ACCRUDEXPENSESANDOTHERCURRENTLIABILITIES(Tables)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","tables","menuCat":"","Tables","order":"","25","firstAnchor":{"contextRef":"","c-1","name":"","us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-1","name":"","us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R26":{"role":"","http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables","longName":"","9954476-Disclosure-STOCKBASEDCOMPENSATION(Tables)","shortName":"","STOCKBASEDCOMPENSATION(Tables)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","tables","menuCat":"","Tables","order":"","26","firstAnchor":{"contextRef":"","c-1","name":"","us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","div","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-1","name":"","us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","div","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R27":{"role":"","http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables","longName":"","9954477-Disclosure-NETLOSSPERSHARE(Tables)","shortName":"","NETLOSSPERSHARE(Tables)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","tables","menuCat":"","Tables","order":"","27","firstAnchor":{"contextRef":"","c-1","name":"","us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","div","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-1","name":"","us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","div","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R28":{"role":"","http://www.blackdiamondtherapeutics.com/role/LEASESTables","longName":"","9954478-Disclosure-LEASES(Tables)","shortName":"","LEASES(Tables)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","tables","menuCat":"","Tables","order":"","28","firstAnchor":{"contextRef":"","c-1","name":"","us-gaap:LeaseCostTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-1","name":"","us-gaap:LeaseCostTableTextBlock","unitRef":"","null","xsiNil":"","false","lang":"","en-US","decimals":"","null","ancestors":{"ix:continuation":"","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R29":{"role":"","http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails","longName":"","9954479-Disclosure-NATUREOFBUSINESSANDBASISOFPRESENTATION(Details)","shortName":"","NATUREOFBUSINESSANDBASISOFPRESENTATION(Details)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","details","menuCat":"","Details","order":"","29","firstAnchor":{"contextRef":"","c-5","name":"","us-gaap:StockIssuedDuringPeriodValueNewsIssues","unitRef":"","usd","xsiNil":"","false","lang":"","en-US","decimals":"","3","ancestors":{"span","td","tr","table","div","us-gaap:SaleOfStockAuthorizedConsideration","unitRef":"","usd","xsiNil":"","false","lang":"","en-US","decimals":"","6","ancestors":{"span","div","ix:continuation","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","unique":true}},"R30":{"role":"","http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails","longName":"","9954480-Disclosure-FAIRVALUEMEASUREMENTS-Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)","shortName":"","FAIRVALUEMEASUREMENTS-Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","details","menuCat":"","Details","order":"","30","firstAnchor":{"contextRef":"","c-74","name":"","us-gaap:AssetsFairValueDisclosure","unitRef":"","usd","xsiNil":"","false","lang":"","en-US","decimals":"","3","ancestors":{"span","td","tr","table","div","us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock","ix:continuation","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-74","name":"","us-gaap:AssetsFairValueDisclosure","unitRef":"","usd","xsiNil":"","false","lang":"","en-US","decimals":"","3","ancestors":{"span","td","tr","table","div","us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock","ix:continuation","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R31":{"role":"","http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleOfMarketableSecuritiesDetails","longName":"","9954481-Disclosure-INVESTMENTS-Schedule of Marketable Securities (Details)","shortName":"","INVESTMENTS-Schedule of Marketable Securities (Details)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","details","menuCat":"","Details","order":"","31","firstAnchor":{"contextRef":"","c-3","name":"","us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis","unitRef":"","usd","xsiNil":"","false","lang":"","en-US","decimals":"","3","ancestors":{"span","td","tr","table","div","us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock","ix:continuation","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-3","name":"","us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis","unitRef":"","usd","xsiNil":"","false","lang":"","en-US","decimals":"","3","ancestors":{"span","td","tr","table","div","us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock","ix:continuation","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R32":{"role":"","http://www.blackdiamondtherapeutics.com/role/INVESTMENTSNarrativeDetails","longName":"","9954482-Disclosure-INVESTMENTS-Narrative (Details)","shortName":"","INVESTMENTS-Narrative (Details)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","details","menuCat":"","Details","order":"","32","firstAnchor":{"contextRef":"","c-1","name":"","us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded","unitRef":"","usd","xsiNil":"","false","lang":"","en-US","decimals":"","INF","ancestors":{"span","td","tr","table","div","us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded","span","div","ix:continuation","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-1","name":"","us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded","unitRef":"","usd","xsiNil":"","false","lang":"","en-US","decimals":"","INF","ancestors":{"span","td","tr","table","div","us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded","span","div","ix:continuation","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R33":{"role":"","http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails","longName":"","9954483-Disclosure-PROPERTYAND-EQUIPMENT(Details)","shortName":"","PROPERTYAND-EQUIPMENT(Details)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","details","menuCat":"","Details","order":"","33","firstAnchor":{"contextRef":"","c-3","name":"","us-gaap:PropertyPlantAndEquipmentGross","unitRef":"","usd","xsiNil":"","false","lang":"","en-US","decimals":"","3","ancestors":{"span","td","tr","table","div","us-gaap:PropertyPlantAndEquipmentTableTextBlock","ix:continuation","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-3","name":"","us-gaap:PropertyPlantAndEquipmentGross","unitRef":"","usd","xsiNil":"","false","lang":"","en-US","decimals":"","3","ancestors":{"span","td","tr","table","div","us-gaap:PropertyPlantAndEquipmentTableTextBlock","ix:continuation","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true}},"R34":{"role":"","http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails","longName":"","9954484-Disclosure-EQUITYMETHODINVESTMENT(Details)","shortName":"","EQUITYMETHODINVESTMENT(Details)","isDefault":"","false","groupType":"","disclosure","subGroupType":"","details","menuCat":"","Details","order":"","34","firstAnchor":{"contextRef":"","c-100","name":"","bdtx:EquityMethodInvestmentSharesReceivedInNoncashExchange","unitRef":"","shares","xsiNil":"","false","lang":"","en-US","decimals":"","INF","ancestors":{"span","div","ix:continuation","body","html"},"reportCount":1,"baseRef":"","bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"","c-100","name":"","bdtx:EquityMethodInvestmentSharesReceivedInNoncashExchange","unitRef":"","shares","xsiNil":"","false","lang":"","en-US","decimals":"","INF","ancestors":{"span","div","ix:

"disclosure","subGroupType":"details","menuCat":"Details","order":"40","firstAnchor":{"contextRef":"c-5","name":"us-gaap:NetIncomeLoss","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"3","ancestors":{"span","td","tr","table","div","us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock","ix:continuation","div","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true},"uniqueAnchor":{"contextRef":null},"R41":{"role":"http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofNetLossperShareDetails","longName":"9954491-Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)","shortName":"NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"41","firstAnchor":{"contextRef":"c-1","name":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","unitRef":"shares","xsiNil":"false","lang":"en-US","decimals":"0","ancestors":{"span","td","tr","table","div","ix:continuation","ix:continuation","div","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"c-1","name":"us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount","unitRef":"shares","xsiNil":"false","lang":"en-US","decimals":"0","ancestors":{"span","td","tr","table","div","ix:continuation","ix:continuation","div","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true,"unique":true}},"R42":{"role":"http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails","longName":"9954492-Disclosure - LEASES - Narrative (Details)","shortName":"LEASES - Narrative (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"42","firstAnchor":{"contextRef":"c-1","name":"bdtx:LesseeOperatingLeaseNumberOfContracts","unitRef":"contract","xsiNil":"false","lang":"en-US","decimals":"INF","ancestors":{"span","div","ix:continuation","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"c-1","name":"bdtx:LesseeOperatingLeaseNumberOfContracts","unitRef":"contract","xsiNil":"false","lang":"en-US","decimals":"INF","ancestors":{"span","div","ix:continuation","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true,"unique":true}},"R43":{"role":"http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails","longName":"9954493-Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)","shortName":"LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"43","firstAnchor":{"contextRef":"c-5","name":"us-gaap:OperatingLeaseCost","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"3","ancestors":{"span","td","tr","table","div","us-gaap:LeaseCostTableTextBlock","ix:continuation","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"c-5","name":"us-gaap:OperatingLeaseCost","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"3","ancestors":{"span","td","tr","table","div","us-gaap:LeaseCostTableTextBlock","ix:continuation","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true,"unique":true}},"R44":{"role":"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails","longName":"9954494-Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)","shortName":"LEASES - Schedule of Future Minimum Lease Payments (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"44","firstAnchor":{"contextRef":"c-3","name":"us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"3","ancestors":{"span","td","tr","table","div","us-gaap:LeaseLiabilityMaturityTableTextBlock","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"c-3","name":"us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"3","ancestors":{"span","td","tr","table","div","ix:continuation","us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true,"unique":true}},"R45":{"role":"http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails","longName":"9954495-Disclosure - BENEFIT PLANS (Details)","shortName":"BENEFIT PLANS (Details)","isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"45","firstAnchor":{"contextRef":"c-1","name":"us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch","unitRef":"number","xsiNil":"false","lang":"en-US","decimals":"2","ancestors":{"span","div","ix:continuation","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true,"unique":true},"uniqueAnchor":{"contextRef":"c-1","name":"us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch","unitRef":"number","xsiNil":"false","lang":"en-US","decimals":"2","ancestors":{"span","div","ix:continuation","body","html"},"reportCount":1,"baseRef":"bdtx-20240630.htm","first":true,"unique":true}}},tag":{"bdtx-A2020EmployeeStockPurchasePlanMember":{"xbrltype":"domainItemType","nsuri":"http://www.blackdiamondtherapeutics.com/20240630","localname":"A2020EmployeeStockPurchasePlanMember","presentation":{"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"2020-ESPP","label":"2020 Employee Stock Purchase Plan [Member]","documentation":"2020 Employee Stock Purchase Plan"}}},"auth-ref":[]},"bdtx-A2020StockOptionPlanMember":{"xbrltype":"domainItemType","nsuri":"http://www.blackdiamondtherapeutics.com/20240630","localname":"A2020StockOptionPlanMember","presentation":{"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"2020 Stock Option Plan","label":"2020 Stock Option Plan [Member]","documentation":"2020 Stock Option Plan"}}},"auth-ref":[]},"us-gaap-AccountingPoliciesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountingPoliciesAbstract"},"lang":{"en-us":{"role":{"label":"Accounting Policies [Abstract]"}}},"auth-ref":[]},"us-gaap-AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock","presentation":{"http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"},"lang":{"en-us":{"role":{"terseLabel":"ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES","label":"Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]","documentation":"The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."}}},"auth-ref":{"r260}}},"us-gaap-AccountsPayableCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountsPayableCurrent","crdr":"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited":{"parentTag":"us-gaap-LiabilitiesCurrent","weight":1.0,"order":1.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Accounts payable","label":"Accounts Payable, Current","documentation":"Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."}}},"auth-ref":{"r29","r477}}},"bdtx-AccruedContractResearchServiceFeesCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://www.blackdiamondtherapeutics.com/20240630","localname":"AccruedContractResearchServiceFeesCurrent","crdr":"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails":{"parentTag":"us-gaap-AccruedLiabilitiesCurrent","weight":1.0,"order":1.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"},"lang":{"en-us":{"role":{"terseLabel":"Contracted research services","label":"Accrued Contract Research Service Fees, Current","documentation":"Accrued Contract Research Service Fees, Current"}}},"auth-ref":{"us-gaap-AccruedLiabilitiesCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccruedLiabilitiesCurrent","crdr":"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited":{"parentTag":"us-gaap-LiabilitiesCurrent","weight":1.0,"order":2.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails":{"parentTag":null,"weight":null,"order":null,"root":true}}},"auth-ref":{"http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"},"lang":{"en-us":{"role":{"terseLabel":"Accrued expenses and other current liabilities","label":"Total accrued expenses and other current liabilities","documentation":"Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."}}},"auth-ref":{"r31}}},"us-gaap-AccruedProfessionalFeesCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccruedProfessionalFeesCurrent","crdr":"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails":{"parentTag":"us-gaap-AccruedLiabilitiesCurrent","weight":1.0,"order":3.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"},"lang":{"en-us":{"role":{"terseLabel":"Professional and consulting fees","label":"Accrued Professional Fees, Current","documentation":"Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."}}},"auth-ref":{"r31}}},"us-gaap-AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment","crdr":"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails":{"parentTag":"us-gaap-PropertyPlantAndEquipmentNet","weight":1.0,"order":2.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"},"lang":{"en-us":{"role":{"negatedTerseLabel":"Less: accumulated depreciation","label":"Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment","documentation":"Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."}}},"auth-ref":{"r22","r91","r379}}},"us-gaap-AccumulatedOtherComprehensiveIncomeLossNetOfTax":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccumulatedOtherComprehensiveIncomeLossNetOfTax","crdr":"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited":{"parentTag":"us-gaap-StockholdersEquity","weight":1.0,"order":4.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Accumulated other comprehensive loss","label":"Accumulated Other Comprehensive Income (Loss), Net of Tax","documentation":"Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."}}},"auth-ref":{"r13","r14","r44","r94","r376","r393","r394}}},"us-gaap-AccumulatedOtherComprehensiveIncomeMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccumulatedOtherComprehensiveIncomeMember","presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Accumulated other comprehensive income (loss)","label":"AOCI Attributable to Parent [Member]","documentation":"Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."}}},"auth-ref":{"r1","r6","r14","r277","r280","r334","r389","r390","r591","r592","r593","r597","r598","r599","r600}}},"ced-Additional402vDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ced/2024","localname":"Additional402vDisclosureTextBlock","presentation":{"http://xbrl.sec.gov/ced/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Additional 402(v) Disclosure","label":"Additional 402(v) Disclosure [Text Block]}}},"auth-ref":{"r526}}},"us-gaap-AdditionalPaidInCapital":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdditionalPaidInCapital","crdr":"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited":{"parentTag":"us-gaap-StockholdersEquity","weight":1.0,"order":3.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Additional paid in capital","label":"Additional Paid in Capital","documentation":"Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."}}},"auth-ref":{"r39","r477","r681}}},"us-gaap-AdditionalPaidInCapitalMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdditionalPaidInCapitalMember","presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Additional paid in capital","label":"Additional Paid in Capital [Member]","documentation":"Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."}}},"auth-ref":{"r398","r597","r598","r599","r600","r662","r682}}},"ced-AdjToCompAmt":{"xbrltype":"monetaryItemType","nsuri":"http://xbrl.sec.gov/ced/2024","localname":"AdjToCompAmt","presentation":{"http://xbrl.sec.gov/ced/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Adjustment to Compensation, Amount","label":"Adjustment to Compensation Amount"}}},"auth-ref":{"r539}}},"ced-AdjToCompAxis":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ced/2024","localname":"AdjToCompAxis","presentation":{"http://xbrl.sec.gov/ced/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Adjustment to Compensation","label":"Adjustment to Compensation [Axis]}}},"auth-ref":{"r539}}},"ced-AdjToNonPeeNeoCompFnTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ced/2024","localname":"AdjToNonPeeNeoCompFnTextBlock","presentation":{"http://xbrl.sec.gov/ced/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Adjustment to Non-PEO NEO Compensation Footnote","label":"Adjustment to Non-PEO NEO Compensation Footnote [Text Block]}}},"auth-ref":{"r539}}},"ced-AdjToPeeCompFnTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ced/2024","localname":"AdjToPeeCompFnTextBlock","presentation":{"http://xbrl.sec.gov/ced/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Adjustment to PEO Compensation, Footnote [Text Block]}}},"auth-ref":{"r539}}},"us-gaap-AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation","crdr":"debit","presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"negatedTerseLabel":"Surrender of shares for taxes","label":"Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation","documentation":"Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."}}},"auth-ref":[]},"us-gaap-AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue","crdr":"credit","presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Stock-based compensation","label":"APIC, Share-Based Payment Arrangement, Increase for Cost Recognition","documentation":"Amount of increase to additional paid in capital (APIC) for recognition of cost for award under share-based payment arrangement."}}},"auth-ref":{"r25","r26","r225}}},"us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract","presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Adjustment to reconcile net loss to net cash used in operating activities","label":"Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]}}},"auth-ref":[]},"ced-AggtChngPnsnValInSummryCompstnTblForApbllyrMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ced/2024","localname":"AggtChngPnsnValInSummryCompstnTblForApbllyrMember"}}

"AggtChngPnsnValInSummaryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": { "r572" }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r498", "r508", "r518", "r550" }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": { "r501", "r511", "r521", "r553" }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": { "r573" }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": { "r539" }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": { "r546" }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": { "r502", "r512", "r522", "r546", "r554", "r558", "r566" }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": { "r564" }, "us-gaap-AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "erdr": "debit", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": { "r254", "r259" }, "dei-AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage" }, "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { } }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because of do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": { "r134" }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": { "r17" }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap-AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because of do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": { "r17" }, "us-gaap-Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "erdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Total assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r68", "r74", "r93", "r111", "r138", "r140", "r142", "r143", "r183", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r272", "r274", "r308", "r372", "r420", "r457", "r458", "r477", "r489", "r628", "r629", "r675" }, "us-gaap-AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": { } }, "us-gaap-AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "erdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r87", "r95", "r111", "r183", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r272", "r274", "r308", "r477", "r628", "r629", "r675" }, "us-gaap-AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": { } }, "us-gaap-AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "erdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosure [Abstract]" } } }, "auth_ref": { } }, "bdtx-AtMarketEquityProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "AtMarketEquityProgramMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" }, "lang": { "en-us": { "role": { "terseLabel": "ATM Program", "label": "At Market Equity Program [Member]", "documentation": "At Market Equity Program" } } }, "auth_ref": { } }, "us-gaap-AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "erdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "parentTag": "us-gaap-AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r152" }, "us-gaap-AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "erdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "parentTag": "us-gaap-AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unrealized Losses", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r153" }, "us-gaap-AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "erdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available for Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r149", "r192", "r371" }, "us-gaap-AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "erdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "parentTag": "us-gaap-AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 3.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available for Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), classified as current." } } }, "auth_ref": { "r146", "r192" }, "ecd-AwardExcrPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExcrPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": { "r561" }, "ecd-AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": { "r562" }, "ecd-AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": { "r557" }, "ecd-AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": { "r557" }, "ecd-AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": { "r557" }, "ecd-AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": { "r557" }, "ecd-AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": { "r557" }, "ecd-AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": { "r557" }, "us-gaap-AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" }, "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": { "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" }, "ecd-AwardUndrlySecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlySecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": { "r560" }, "ecd-AwardsCloseToMnpiDiscName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscName", "presentation": {

```

{"url": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terselabel": "Name", "label": "Awards Close In Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": { "r559" } }, "ecd_AwardsCloseToMnpiDisclosureTable": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDisclosureTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terselabel": "Awards Close In Time to MNPI Disclosures, Table", "label": "Awards Close In Time to MNPI Disclosures [Table]" } } }, "auth_ref": { "r558" } }, "ecd_AwardsCloseToMnpiDisclosureTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDisclosureTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terselabel": "Awards Close In Time to MNPI Disclosures, Table", "label": "Awards Close In Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": { "r558" } }, "us_gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "lang": { "en-us": { "role": { "terselabel": "Principles of consolidation and unaudited interim financial information", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": { "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "lang": { "en-us": { "role": { "terselabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r551" } }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION", "lang": { "en-us": { "role": { "terselabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": { "r28", "r55", "r56" } }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "order": { "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "terselabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, end of period", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": { "r16", "r89", "r452" } }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "order": { "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "lang": { "en-us": { "role": { "terselabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r664", "r665" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "order": { "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "totalLabel": "Cash, cash equivalents and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r16", "r52", "r110" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terselabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": { "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "order": { "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r0", "r52" } }, "ecd_ChangedPeerGroupPvpDisclosure": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupPvpDisclosure", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terselabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": { "r537" } }, "ecd_ChngInFrValAsOfVstngDtOPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terselabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": { "r534" } }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terselabel": "Year-over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": { "r532" } }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage", "lang": { "en-us": { "role": { "terselabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": { "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terselabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": { "r538" } }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terselabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": { "r538" } }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "lang": { "en-us": { "role": { "terselabel": "Commercial paper", "verboseLabel": "Commercial paper", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents." } } }, "auth_ref": { "r630" } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "order": { "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "terselabel": "Commitments and contingencies (Note 000a011)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r35", "
```

"lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": { "r543" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": { "r542" } }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": { "r544" } }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": { "r541" } } }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS": { "lang": { "en-us": { "role": { "terseLabel": "BENEFIT PLANS", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": { "r62", "r63", "r64", "r65" } } }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": { "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited": { "lang": { "en-us": { "role": { "totallabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r15", "r99", "r101", "r105", "r368", "r384", "r385" } } }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": { "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES": { "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": { "r27", "r453" } } }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSchedulofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSSchedulofMarketableSecuritiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": { "doi_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": { "doi_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." } } }, "auth_ref": { "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "crdr": "debit", "presentation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Impairment of fair value assets", "label": "Debt Securities, Available for Sale, Allowance for Credit Loss, Not Previously Recorded", "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), for which no credit loss was previously recorded." } } }, "auth_ref": { "r196" } } }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSSchedulofMarketableSecuritiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available for sale [Table]", "label": "Debt Securities, Available for Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159" } } }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Marketable Securities", "label": "Debt Securities, Available for Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620" } } }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": { "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Employer contribution amount", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": { "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": { "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Employer contribution, percent of each participant's salary", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": { "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": { "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Employer contribution, matching contribution percentage", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": { "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": { "r4", "r21" } } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION": { "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r223", "r227", "r255", "r256", "r258", "r465" } } }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": { "doi_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { "doi_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { "doi_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { "doi_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": { "r493" } } }, "doi_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r525" } } }, "doi_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "DocumentType", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": { "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": { "r536" } } }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": { "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic (in dollars per share)", "label": "Net loss per share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r106", "r117", "r118", "r119", "r120", "r121", "r122", "r127", "r129", "r131", "r132", "r133", "r137", "r268", "r271", "r284", "r285", "r369", "r386", "r454" } } }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted (in dollars per share)", "label": "Net loss per share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r106", "r117", "r118", "r119", "r120", "r121", "r122", "r129", "r131", "r132", "r133", "r137", "r268", "r271", "r284", "r285", "r369", "r386", "r454" } } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE": { "lang": { "en-us": { "role": { "terseLabel": "NET LOSS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r126", "r134", "r135", "r136" } } }, "bdtx_ElizabethBuckMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "ElizabethBuckMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Elizabeth Buck [Member]", "documentation": "Elizabeth Buck" } } }, "auth_ref": { "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "us-gaap_AcruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payroll and related expenses", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current

portion of the liabilities (due within one year or within the normal operating cycle if longer)."}}, {"auth_ref": {"r31": ""}, "us_gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}], {"auth_ref": {}}, {"us_gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Unrecognized compensation cost, recognition period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PaYnMdTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."}}}], {"auth_ref": {"r257": ""}, "us_gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"}, {"errdr": "debit", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."}}}], {"auth_ref": {"r657": ""}, "us_gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"}, {"errdr": "debit", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Unrecognized compensation cost, options", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."}}}], {"auth_ref": {"r657": ""}, "us_gaap_EmployeeStockMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"}, {"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"}, {"http://xbrl.sec.gov/ced/role/AwardTimingDisclosure"}, {"lang": {"en-us": {"role": {"terseLabel": "Shares issuable under employee stock purchase plan", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax efficient means by which employees of a corporation can purchase the corporation's stock."}}}], {"auth_ref": {}}, {"us_gaap_EmployeeStockOptionMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"}, {"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"}, {"http://xbrl.sec.gov/ced/role/AwardTimingDisclosure"}, {"lang": {"en-us": {"role": {"terseLabel": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."}}}], {"auth_ref": {}}, {"dei_EntityAddressAddressLine1": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name"}}}], {"auth_ref": {}}, {"dei_EntityAddressCityOrTown": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town"}}}], {"auth_ref": {}}, {"dei_EntityAddressPostalZipCode": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code"}}}], {"auth_ref": {}}, {"dei_EntityAddressStateOrProvince": {"xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province."}}}], {"auth_ref": {}}, {"dei_EntityCentralIndexKey": {"xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."}}}], {"auth_ref": {"r491": ""}, {"dei_EntityCommonStockSharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."}}}], {"auth_ref": {}}, {"dei_EntityCurrentReportingStatus": {"xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."}}}], {"auth_ref": {}}, {"dei_EntityEmergingGrowthCompany": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria."}}}], {"auth_ref": {"r491": ""}, {"dei_EntityExTransitionPeriod": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."}}}], {"auth_ref": {"r576": ""}, {"dei_EntityFileNumber": {"xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."}}}], {"auth_ref": {}}, {"dei_EntityFilerCategory": {"xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."}}}], {"auth_ref": {"r491": ""}, {"dei_EntityIncorporationStateCountryCode": {"xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two character EDGAR code representing the state or country of incorporation."}}}], {"auth_ref": {}}, {"dei_EntityInteractiveDataCurrent": {"xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."}}}}], {"auth_ref": {"r575": ""}, {"dei_EntityRegistrantName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."}}}], {"auth_ref": {"r491": ""}, {"dei_EntityShellCompany": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."}}}], {"auth_ref": {"r491": ""}, {"dei_EntitySmallBusiness": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."}}}}], {"auth_ref": {"r491": ""}, {"dei_EntityTaxIdentificationNumber": {"xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}, {"lang": {"en-us": {"role": {"terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."}}}], {"auth_ref": {"r491": ""}, {"ced_EqtyAwrdsAdjFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "EqtyAwrdsAdjFnTextBlock"}, {"presentation": [{"http://xbrl.sec.gov/ced/role/PvpDisclosure"}, {"lang": {"en-us": {"role": {"terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]"}}}}], {"auth_ref": {"r530": ""}, {"ced_EqtyAwrdsAdjExclgValRprtdInSummaryCompstnTblMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "EqtyAwrdsAdjExclgValRprtdInSummaryCompstnTblMember"}, {"presentation": [{"http://xbrl.sec.gov/ced/role/PvpDisclosure"}, {"lang": {"en-us": {"role": {"terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"}}}}], {"auth_ref": {"r571": ""}, {"ced_EqtyAwrdsAdjJsMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "EqtyAwrdsAdjJsMember"}, {"presentation": [{"http://xbrl.sec.gov/ced/role/PvpDisclosure"}, {"lang": {"en-us": {"role": {"terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]"}}}}], {"auth_ref": {"r571": ""}, {"ced_EqtyAwrdsInSummaryCompstnTblForApblYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "EqtyAwrdsInSummaryCompstnTblForApblYrMember"}, {"presentation": [{"http://xbrl.sec.gov/ced/role/PvpDisclosure"}, {"lang": {"en-us": {"role": {"terseLabel": "Aggregate Grant-Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant-Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"}}}}], {"auth_ref": {"r571": ""}, {"us_gaap_EquityComponentDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}, {"lang": {"en-us": {"role": {"terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."}}}], {"auth_ref": {"r7": "r85", "r102": "r103", "r104", "r112", "r113", "r114", "r116", "r121", "r123", "r125", "r130", "r185", "r186", "r197", "r216", "r262", "r263", "r265", "r266", "r267", "r269", "r270", "r271", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r317", "r334", "r382", "r389", "r390", "r391", "r398", "r446"}}, {"err_EquityMethodInvesteeNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]"}}}}], {"auth_ref": {"r179", "r180", "r182", "r264", "r577", "r578", "r579", "r658", "r659", "r660", "r661"}}, {"us_gaap_EquityMethodInvestmentOwnershipPercentage": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Equity method investment, ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."}}}], {"auth_ref": {"r170": ""}, {"bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange": {"xbrltype": "sharesItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "EquityMethodInvestmentSharesReceivedInNoncashExchange"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Common shares received from equity method investment (in shares)", "label": "Equity Method Investment, Shares Received in Noncash Exchange", "documentation": "Equity Method Investment, Shares Received in Noncash Exchange"}}}], {"auth_ref": {}}, {"us_gaap_EquityMethodInvestments": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments"}, {"errdr": "debit", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"}, {"lang": {"en-us": {"role": {"terseLabel": "Equity Method Investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."}}}], {"auth_ref": {"r138", "r141", "r143", "r178", "r588", "r624"}}, {"us_gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract"}, {"lang": {"en-us": {"role": {"label": "Equity Method Investments and Joint Ventures [Abstract]"}}}}], {"auth_ref": {}}, {"us_gaap_EquityMethodInvestmentsDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsDisclosureTextBlock"}, {"presentation": [{"http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT"}, {"lang": {"en-us": {"role": {"terseLabel": "EQUITY METHOD INVESTMENT", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the

group" } } } }, "auth_ref": { "r83", "r181", "r184", "r579" } }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": { "r540" } }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": { "r498", "r508", "r518", "r550" } }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": { "r495", "r505", "r515", "r547" } }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Executive Category", "label": "Executive Category [Axis]" } } }, "auth_ref": { "r546" } } }, "us_gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r287", "r288", "r298", "r466" } }, "us_gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": { "r287", "r288", "r298", "r466" } } }, "us_gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": { "r212", "r217", "r218", "r219", "r220", "r221", "r222", "r286", "r288", "r289", "r290", "r291", "r297", "r298", "r300", "r338", "r339", "r340", "r460", "r461", "r462", "r463", "r464", "r466", "r469" } } }, "us_gaap_FairValueByFairValueHierarchyLevelTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelTable", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": { "r287", "r288", "r289", "r291", "r466", "r667", "r670" } } }, "us_gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": { } } }, "us_gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" }, "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": { "r293", "r295", "r296", "r297", "r300", "r301", "r302", "r303", "r304", "r366", "r466", "r470" } } }, "us_gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": { "r212", "r217", "r222", "r288", "r298", "r338", "r462", "r463", "r464", "r466" } } }, "us_gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": { "r212", "r217", "r222", "r288", "r289", "r298", "r339", "r460", "r461", "r462", "r463", "r464", "r466" } } }, "us_gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Level 00a03", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": { "r212", "r217", "r218", "r219", "r220", "r221", "r222", "r288", "r289", "r290", "r291", "r298", "r340", "r460", "r461", "r462", "r463", "r464", "r466", "r469" } } }, "us_gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": { "r287", "r288", "r289", "r291", "r466", "r667", "r670" } } }, "us_gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": { "r212", "r217", "r218", "r219", "r220", "r221", "r222", "r286", "r288", "r289", "r290", "r291", "r297", "r298", "r300", "r338", "r339", "r340", "r460", "r461", "r462", "r463", "r464", "r466", "r469" } } } }, "us_gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": { "r466", "r664", "r665", "r666", "r667", "r668", "r670" } } }, "us_gaap_FinancialInstrumentAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": { "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r187", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r213", "r215", "r292", "r305", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r383", "r450", "r466", "r467", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r478", "r581", "r582", "r583", "r584", "r585", "r586", "r597", "r620", "r621", "r622", "r623", "r663", "r664", "r666", "r667", "r668", "r669" } } }, "bdtx_FollowOnOfferingMember": { "xbrltype": "domainItem", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "FollowOnOfferingMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFFPRESENTATIONDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Follow on Offering", "label": "Follow on Offering [Member]", "documentation": "Follow on Offering" } } }, "auth_ref": { } } }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": { "r502", "r512", "r522", "r554" } } }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": { "r502", "r512", "r522", "r554" } } }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": { "r502", "r512", "r522", "r554" } } }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": { "r502", "r512", "r522", "r554" } } }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": { "r502", "r512", "r522", "r554" } } }, "ecd_FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Prior Year That Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year That Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": { "r535" } } }, "us_gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": { } } }, "bdtx_GainLossOnSaleOfEquipment": { "xbrltype": "monetaryItem", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "GainLossOnSaleOfEquipment", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "parentTag": "us_gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "negatedLabel": "(Gain) Loss on sale of equipment", "label": "(Gain) Loss on Sale of Equipment", "documentation": "Gain (Loss) on Sale of Equipment" } } }, "auth_ref": { } } }, "us_gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "parentTag": "us_gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": { "r46", "r430" } } }, "us_gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": { "r46" } } }, "us_gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": { "r198", "r199", "r200", "r292", "r294", "r299", "r387", "r388", "r431", "r451", "r468", "r679" } } }, "us_gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Income Statement Location [Domain]","label":"Statement of Income Location, Balance [Domain]","documentation":"Location in statement of income where disaggregated amount has been reported."}}},"auth_ref":{"r199","r200","r292","r294","r299","r387","r388","r431","r451","r468","r679"}}},"us-gaap-IncreaseDecreaseInAccountsPayableTrade":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInAccountsPayableTrade"},"crdr":{"debit","calculation":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":8.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Accounts payable","label":"Increase (Decrease) in Accounts Payable, Trade","documentation":"Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."}}},"auth_ref":{"r3"}"},"us-gaap-IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"},"crdr":{"debit","calculation":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":4.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Accrued expenses and other current liabilities","label":"Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities","documentation":"Amount of increase (decrease) in accrued expenses, and obligations classified as other."}}},"auth_ref":{"r594"}}},"us-gaap-IncreaseDecreaseInOperatingCapitalAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInOperatingCapitalAbstract"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Changes in current assets and liabilities","label":"Increase (Decrease) in Operating Capital [Abstract]"}}}},"auth_ref":{"}}},"bdtx-IncreaseDecreaseInOperatingLeaseLiabilities":{"xbrltype":"monetaryItemType","nsuri":"http://www.blackdiamondtherapeutics.com/20240630","localname":"IncreaseDecreaseInOperatingLeaseLiabilities"},"crdr":{"debit","calculation":{"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":5.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Non-current operating lease liabilities","label":"Increase (Decrease) in Operating Lease Liabilities","documentation":"Increase (Decrease) in Operating Lease Liabilities"}}}},"auth_ref":{"}}},"us-gaap-IncreaseDecreaseInOtherNoncurrentAssets":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInOtherNoncurrentAssets"},"crdr":{"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":11.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"lang":{"en-us":{"role":{"negatedTerseLabel":"Other non-current assets","label":"Increase (Decrease) in Other Noncurrent Assets","documentation":"Amount of increase (decrease) in noncurrent assets classified as other."}}},"auth_ref":{"r594"}}},"us-gaap-IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"},"crdr":{"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":6.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"lang":{"en-us":{"role":{"negatedLabel":"Prepaid expenses and other current assets","label":"Increase (Decrease) in Prepaid Expense and Other Assets","documentation":"Amount of increase (decrease) in prepaid expenses, and assets classified as other."}}},"auth_ref":{"r3"}"},"us-gaap-IncreaseDecreaseInStockholdersEquityRollForward":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"IncreaseDecreaseInStockholdersEquityRollForward"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"},"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"},"lang":{"en-us":{"role":{"terseLabel":"Increase (Decrease) in Stockholders' Equity [Roll Forward]","label":"Increase (Decrease) in Stockholders' Equity [Roll Forward]","documentation":"A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."}}},"auth_ref":{"}}},"ecd-IndividualAxis":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"IndividualAxis"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"},"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Individual","label":"Individual [Axis]"}}}},"auth_ref":{"r502","r512","r522","r546","r554","r558","r566"}}},"ecd-InsiderTradingArrLineItems":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTradingArrLineItems"},"lang":{"en-us":{"role":{"label":"Insider Trading Arrangements [Line Items]"},"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTradingPoliciesProcLineItems"},"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTradingPoliciesProcLineItems"},"lang":{"en-us":{"role":{"label":"Insider Trading Policies and Procedures [Line Items]"}}}},"auth_ref":{"r494","r570"}}},"ecd-InsiderTrdPoliciesProcAdoptedFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTrdPoliciesProcAdoptedFlag"},"presentation":{"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"},"lang":{"en-us":{"role":{"terseLabel":"Insider Trading Policies and Procedures Adopted","label":"Insider Trading Policies and Procedures Adopted [Flag]"}}}},"auth_ref":{"r494","r570"}}},"ecd-InsiderTrdPoliciesProcNotAdoptedTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"InsiderTrdPoliciesProcNotAdoptedTextBlock"},"presentation":{"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"},"lang":{"en-us":{"role":{"terseLabel":"Insider Trading Policies and Procedures Not Adopted","label":"Insider Trading Policies and Procedures Not Adopted [Text Block]"}}}},"auth_ref":{"r494","r570"}}},"us-gaap-InvestmentIncomeNetAmortizationOfDiscountAndPremium":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InvestmentIncomeNetAmortizationOfDiscountAndPremium"},"crdr":{"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"parentTag":"us-gaap_NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":1.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"},"lang":{"en-us":{"role":{"negatedTerseLabel":"(Accretion) amortization on investments","label":"Investment Income, Net, Amortization of Discount and Premium","documentation":"Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."}}},"auth_ref":{"r48"}"},"us-gaap-InvestmentIncomeNonoperating":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InvestmentIncomeNonoperating"},"crdr":{"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited"},"parentTag":"us-gaap_NonoperatingIncomeExpense","weight":1.0,"order":1.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Interest income","label":"Investment Income, Nonoperating","documentation":"The aggregate amount of income from investments (for example, dividends not considered a component of the entity's core operations."}}},"auth_ref":{"r47"}"},"us-gaap-InvestmentsDebtAndEquitySecuritiesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InvestmentsDebtAndEquitySecuritiesAbstract"},"lang":{"en-us":{"role":{"label":"Investments, Debt and Equity Securities [Abstract]"}}}},"auth_ref":{"}}},"us-gaap-InvestmentsFairValueDisclosure":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InvestmentsFairValueDisclosure"},"crdr":{"debit","calculation":{"http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSchedulofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"},"parentTag":"us-gaap_AssetsFairValueDisclosure","weight":1.0,"order":2.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSchedulofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"},"lang":{"en-us":{"role":{"terseLabel":"Investments","label":"Investments, Fair Value Disclosure","documentation":"Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."}}},"auth_ref":{"r664","r665","r669"}}},"us-gaap-InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/INVESTMENTS"},"lang":{"en-us":{"role":{"terseLabel":"INVESTMENTS","label":"Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]","documentation":"The entire disclosure for investments in certain debt and equity securities."}}},"auth_ref":{"r72","r84","r145","r147","r306","r307","r678"}"},"us-gaap-LeaseContractualTermAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseContractualTermAxis"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Lease Contractual Term [Axis]","label":"Lease Contractual Term [Axis]","documentation":"Information by contractual term of lease arrangement."}}},"auth_ref":{"r333","r580"}}},"us-gaap-LeaseContractualTermDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseContractualTermDomain"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Lease Contractual Term [Domain]","label":"Lease Contractual Term [Domain]","documentation":"Contractual term of lease arrangement."}}},"auth_ref":{"r333","r580"}}},"us-gaap-LeaseCost":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseCost"},"crdr":{"debit","calculation":{"http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"},"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"},"lang":{"en-us":{"role":{"totalLabel":"Total lease cost","label":"Lease, Cost","documentation":"Amount of lease cost recognized by lessee for lease contract."}}},"auth_ref":{"r323","r476"}}},"us-gaap-LeaseCostAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseCostAbstract"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Lease Cost","label":"Lease, Cost [Abstract]"}}}},"auth_ref":{"}}},"us-gaap-LeaseCostTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseCostTableTextBlock"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESTables"},"lang":{"en-us":{"role":{"terseLabel":"Schedule of Lease Cost and Other Operating Lease Information","label":"Lease, Cost [Table Text Block]","documentation":"Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."}}},"auth_ref":{"r673}}},"bdtx-LeaseOtherInformationAbstract":{"xbrltype":"stringItemType","nsuri":"http://www.blackdiamondtherapeutics.com/20240630","localname":"LeaseOtherInformationAbstract"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"Other Operating Lease Information","label":"Lease, Other Information [Abstract]","documentation":"Lease, Other Information [Abstract]"}}}},"auth_ref":{"}}},"us-gaap-LeaseholdImprovementsMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseholdImprovementsMember"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"},"lang":{"en-us":{"role":{"terseLabel":"Leasehold improvements","label":"Leasehold Improvements [Member]","documentation":"Additions or improvements to assets held under a lease arrangement."}}},"auth_ref":{"r59","r332"}}},"us-gaap-LeasesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeasesAbstract"},"lang":{"en-us":{"role":{"label":"Leases [Abstract]"}}}},"auth_ref":{"}}},"us-gaap-LesseeLeaseDescriptionLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeLeaseDescriptionLineItems"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Lessee, Lease, Description [Line Items]","label":"Lessee, Lease, Description [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":{"r322","r333"}}},"us-gaap-LesseeLeaseDescriptionTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeLeaseDescriptionTable"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Lessee, Lease, Description [Table]","label":"Lessee, Lease, Description [Table]","documentation":"Disclosure of information about lessee's leases."}}},"auth_ref":{"r322","r333"}}},"bdtx-LesseeOperatingLeaseArea":{"xbrltype":"areaItemType","nsuri":"http://www.blackdiamondtherapeutics.com/20240630","localname":"LesseeOperatingLeaseArea"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Area leased (square-foot)","label":"Lessee, Operating Lease, Area","documentation":"Lessee, Operating Lease, Area"}}}},"auth_ref":{"}}},"us-gaap-LesseeOperatingLeaseLiabilityMaturityTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityMaturityTableTextBlock"},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESTables"},"lang":{"en-us":{"role":{"terseLabel":"Schedule of Future Minimum Lease Payments","label":"Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]","documentation":"Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."}}},"auth_ref":{"r674"}}},"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsDue"},"crdr":{"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/LEASESSchedulofFutureMinimumLeasePaymentsDetails"},"parentTag":null,"weight":null,"order":null,"root":true},"http://www.blackdiamondtherapeutics.com/role/LEASESSchedulofFutureMinimumLeasePaymentsDetails"},"lang":{"en-us":{"role":{"totalLabel":"Total lease payments","label":"Lessee, Operating Lease, Liability, to be Paid","documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease."}}},"auth_ref":{"r331"}}},"bdtx-LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour":{"xbrltype":"monetaryItemType","nsuri":"http://www.blackdiamondtherapeutics.com/20240630","localname":"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"},"crdr":{"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/LEASESSchedulofFutureMinimumLeasePaymentsDetails"},"parentTag":"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":6.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESSchedulofFutureMinimumLeasePaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Thereafter","label":"Lessee, Operating Lease, Liability, Payments, Due after Year Four","documentation":"Lessee, Operating Lease, Liability, Payments, Due after Year Four"}}}},"auth_ref":{"}}},"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"},"crdr":{"credit","calculation":{"http://www.blackdiamondtherapeutics.com/role/LEASESSchedulofFutureMinimumLeasePaymentsDetails"},"parentTag":"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":2.0},"presentation":{"http://www.blackdiamondtherapeutics.com/role/LEASESSchedulofFutureMinimumLeasePaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"2025","label":"Lessee, Operating Lease, Liability, to be Paid, Year One","documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next

first fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, {"auth_ref": {"r331"}}, {"us_gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "credit": "calculation": {"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, {"auth_ref": {"r331"}}, {"us_gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "credit": "calculation": {"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, {"auth_ref": {"r331"}}, {"us_gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "credit": "calculation": {"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, {"auth_ref": {"r331"}}, {"us_gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "credit": "calculation": {"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "2024 (excluding the six months ended June30, 2024)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, {"auth_ref": {"r674"}}, {"us_gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "credit": "calculation": {"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {"lang": {"en-us": {"role": {"negatedTerseLabel": "Less: interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, {"auth_ref": {"r331"}}, {"bdtx_LesseeOperatingLeaseNumberOfContracts": {"xbrltype": "integerItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "LesseeOperatingLeaseNumberOfContracts", "presentation": {"http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of leases", "label": "Lessee, Operating Lease, Number Of Contracts", "documentation": "Lessee, Operating Lease, Number Of Contracts" } } }, {"auth_ref": {"r331"}}, {"us_gaap_LesseeOperatingLeaseRenewalTerm": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": {"http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Lease term, optional extension (in years)", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, {"auth_ref": {"r672"}}, {"us_gaap_LesseeOperatingLeaseTermOfContract": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": {"http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Lease term (in years)", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, {"auth_ref": {"r672"}}, {"us_gaap_LesseeOperatingLeasesTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": {"http://www.blackdiamondtherapeutics.com/role/LEASES": {"lang": {"en-us": {"role": {"terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, {"auth_ref": {"r316"}}, {"us_gaap_LettersOfCreditOutstandingAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "credit": "calculation": {"http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Letter of credit outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, {"auth_ref": {}}, {"us_gaap_Liabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "credit": "calculation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {"lang": {"en-us": {"role": {"totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, {"auth_ref": {"r12", "r30", "r31", "r32", "r33", "r34", "r35", "r36", "r111", "r183", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r273", "r274", "r275", "r308", "r406", "r455", "r489", "r628", "r675", "r676"}}, {"us_gaap_LiabilitiesAndStockholdersEquity": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "credit": "calculation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {"parentTag": null, "weight": null, "order": null, "root": true}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {"lang": {"en-us": {"role": {"totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, {"auth_ref": {"r43", "r70", "r378", "r477", "r596", "r625", "r671"}}, {"us_gaap_LiabilitiesAndStockholdersEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {"lang": {"en-us": {"role": {"terseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, {"auth_ref": {}}, {"us_gaap_LiabilitiesCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "credit": "calculation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {"parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {"lang": {"en-us": {"role": {"totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, {"auth_ref": {"r32", "r88", "r111", "r183", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r273", "r274", "r275", "r308", "r477", "r628", "r675", "r676"}}, {"us_gaap_LiabilitiesCurrentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {"lang": {"en-us": {"role": {"terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, {"auth_ref": {}}, {"dei_LocalPhoneNumber": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": {"http://www.blackdiamondtherapeutics.com/role/CoverPage": {"lang": {"en-us": {"role": {"terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, {"auth_ref": {}}, {"eod_MeasureAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "MeasureAxis", "presentation": {"http://xbrl.sec.gov/eod/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Measure", "label": "Measure [Axis]" } } }, {"auth_ref": {"r538"}}, {"eod_MeasureName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "MeasureName", "presentation": {"http://xbrl.sec.gov/eod/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Name", "label": "Measure Name" } } }, {"auth_ref": {"r538"}}, {"eod_MnpiDiscTimedForCompValFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": {"http://xbrl.sec.gov/eod/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, {"auth_ref": {"r557"}}, {"us_gaap_MoneyMarketFundsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": {"http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {"lang": {"en-us": {"role": {"terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, {"auth_ref": {"r630"}}, {"eod_MtrlTermsOfTrdArrTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": {"http://xbrl.sec.gov/eod/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, {"auth_ref": {"r565"}}, {"eod_NamedExecutiveOfficersFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": {"http://xbrl.sec.gov/eod/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, {"auth_ref": {"r539"}}, {"us_gaap_NetCashProvidedByUsedInFinancingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "credit": "debit", "calculation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, {"auth_ref": {"r109"}}, {"us_gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, {"auth_ref": {}}, {"us_gaap_NetCashProvidedByUsedInInvestingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "credit": "debit", "calculation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, {"auth_ref": {"r109"}}, {"us_gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, {"auth_ref": {}}, {"us_gaap_NetCashProvidedByUsedInOperatingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, {"auth_ref": {"r52", "r53", "r54"}}, {"us_gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {"lang": {"en-us": {"role": {"terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, {"auth_ref": {}}, {"us_gaap_NetIncomeLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "credit": "debit", "calculation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited": {"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0}}, {"presentation": {"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLoserShareDetails", "http://xbrl.sec.gov/eod/role/PvpDisclosure": {"lang": {"en-us": {"role": {

```

"Net-loss", "Net-loss", "Net-loss", "Net-loss", "Net Income (Loss) Attributable to Parent", "documentation", "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } }, "auth-ref": { "r45", "r54", "r71", "r86", "r98", "r100", "r104", "r111", "r115", "r117", "r118", "r119", "r120", "r121", "r124", "r125", "r130", "r183", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r268", "r271", "r285", "r308", "r381", "r428", "r444", "r445", "r487", "r628" } }, "us-gaap-NonAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "lang": { "en-us": { "role": { "terseLabel": "Recently issued accounting pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth-ref": { } }, "ecd-NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth-ref": { "r538" } }, "ecd-NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth-ref": { "r502", "r512", "r522", "r546", "r554" } }, "ecd-NonPeeNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth-ref": { "r529" } }, "ecd-NonPeeNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth-ref": { "r528" } }, "ecd-NonPeeNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth-ref": { "r546" } }, "ecd-NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth-ref": { "r565" } }, "ecd-NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth-ref": { "r565" } }, "us-gaap-NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth-ref": { "r47" } }, "us-gaap-NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth-ref": { "r14" } }, "us-gaap-OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth-ref": { } }, "us-gaap-OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth-ref": { } }, "us-gaap-OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth-ref": { "r73", "r456", "r602", "r603", "r604", "r605", "r606" } }, "us-gaap-OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "parentTag": "us-gaap-LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth-ref": { "r324", "r476" } }, "us-gaap-OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth-ref": { } }, "us-gaap-OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Total lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth-ref": { "r319" } }, "us-gaap-OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "us-gaap-AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth-ref": { "r319" } }, "us-gaap-OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth-ref": { "r320" } }, "us-gaap-OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Non-current operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth-ref": { "r319" } }, "bdtX-OperatingLeaseOfficeAndLaboratorySpaceNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "OperatingLeaseOfficeAndLaboratorySpaceNYMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Office and Laboratory Space, NY", "label": "Operating Lease, Office and Laboratory Space, NY [Member]", "documentation": "Operating Lease, Office and Laboratory Space, NY" } } }, "auth-ref": { } }, "us-gaap-OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liability", "label": "Operating Lease, Payments", "documentation": "
```

"en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } }, "auth-ref": { "r49" } }, "eecd-OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth-ref": { "r538" } }, "eecd-OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/eecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth-ref": { "r500", "r510", "r520", "r552" } }, "eecd-OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/eecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth-ref": { "r503", "r513", "r523", "r555" } }, "eecd-OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/eecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth-ref": { "r503", "r513", "r523", "r555" } }, "eecd-PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth-ref": { "r527" } }, "us-gaap-PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth-ref": { } }, "us-gaap-PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth-ref": { "r51" } }, "eecd-PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth-ref": { "r537" } }, "eecd-PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth-ref": { "r537" } }, "eecd-PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth-ref": { "r529" } }, "eecd-PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth-ref": { "r546" } }, "eecd-PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth-ref": { "r539" } }, "eecd-PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth-ref": { "r528" } }, "bdtx-PerformanceRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "PerformanceRestrictedStockUnitsMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/eecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Performance restricted stock units", "label": "Performance Restricted Stock Units [Member]", "documentation": "Performance Restricted Stock Units" } } }, "auth-ref": { } }, "us-gaap-PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/eecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Unvested performance restricted stock units", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth-ref": { } }, "us-gaap-PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth-ref": { "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656" } }, "us-gaap-PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth-ref": { "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656" } }, "eecd-PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth-ref": { "r530" } }, "eecd-PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth-ref": { "r574" } }, "eecd-PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth-ref": { "r529" } }, "us-gaap-PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth-ref": { "r37", "r214" } }, "us-gaap-PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth-ref": { "r37", "r408" } }, "us-gaap-PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth-ref": { "r37", "r214" } }, "us-gaap-PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth-ref": { "r37", "r408", "r426", "r682", "r683" } }, "us-gaap-PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, \$0.0001 par value, 10,000,000 shares authorized at June30u00a02024 and Decemberu00a02023; no shares issued or outstanding at June30u00a02024 and Decemberu00a02023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth-ref": { "r37", "r374", "r477" } }, "us-gaap-PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth-ref": { "r590" } }, "us-gaap-ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth-ref": { "r2" } }, "us-gaap-ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of common stock options and ESPP", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth-ref": { "r2", "r10" } }, "us-gaap-ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "lang": { "en-us": { "role": { "terseLabel": "Proceeds from equity financing", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth-ref": { "r2", "r396" } }, "us-gaap-ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth-ref": { "r50" } }, "us-gaap-PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth-ref": { } }, "us-gaap-PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth-ref": { "r5", "r332" } }, "us-gaap-PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT", "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth-ref": { "r58", "r78", "r81", "r82" } }, "us-gaap-PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "parentTag": "us-gaap-PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth-ref": { "r59", "r90", "r380" } }, "us-gaap-PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": { "r332" } }, "us-gaap-PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": {

"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"; { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 2.0 },
"http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"; { "parentTag": "null", "weight": "null", "order": "null", "root": "true" } }, "presentation": {
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"; "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails";
"lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Total Property and Equipment, net", "label": "Property, Plant and Equipment, Net", "documentation":
"Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale.
Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth-ref": { "r5": "r332", "r370", "r380", "r477" } }, "us-gaap-PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables"; "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label":
"Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth-ref": { "r5" } },
"us-gaap-PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain",
"presentation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"; "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type
[Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth-ref": { "r59", "r332" } }, "ecd-PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"; "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure
[Table]"; } }, "auth-ref": { "r527" } }, "ecd-PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"; "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]"; } } },
"auth-ref": { "r527" } }, "ecd-RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"; } } }, "auth-ref": { "r495", "r505",
"r515", "r547" } }, "bdtx-RentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "RentExpense", "crdr": "debit",
"calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"; { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"; "lang": { "en-us": { "role": { "terseLabel": "Noncash rent expense", "label": "Rent
Expense", "documentation": "Rent Expense"; } } }, "auth-ref": { } }, "us-gaap-ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited"; { "parentTag": "us-gaap-OperatingExpenses", "weight":
1.0, "order": 1.0 } }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited"; "lang": { "en-us": {
"role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth-ref": { "r261", "r451", "r457", "r677" } }, "us-gaap-ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"; "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth-ref": { } }, "ecd-RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis",
"presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"; "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date
[Axis]"; } } }, "auth-ref": { "r496", "r506", "r516", "r548" } }, "ecd-RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"; "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label":
"Restatement Determination Date"; } } }, "auth-ref": { "r497", "r507", "r517", "r549" } }, "ecd-RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"; "lang": { "en-us": { "role": {
"terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]"; } } }, "auth-ref": { "r504", "r514", "r524", "r556" } }, "us-gaap-RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": {
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"; { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight":
1.0, "order": 2.0 },
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"; { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"; "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "verboseLabel":
"Restricted cash, end of period", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth-ref": { "r75", "r589", "r595" } }, "us-gaap-RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails"; "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"; "lang": {
"en-us": { "role": { "terseLabel": "Unvested restricted stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth-ref": { "r17" } }, "us-gaap-RestrictedStockUnitsRSUMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"; "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"; "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"; "lang": {
"en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth-ref": { } }, "us-gaap-RetainedEarningsAccumulatedDeficit": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"; { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"; "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth-ref": { "r40", "r61", "r377", "r392", "r394", "r397", "r409", "r477" } }, "us-gaap-RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"; "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth-ref": { "r85", "r112", "r113", "r114", "r116", "r121", "r123", "r125", "r185", "r186", "r197", "r262", "r263", "r265", "r266", "r267", "r269", "r270", "r271", "r276", "r278", "r279", "r281", "r283", "r315", "r317", "r389", "r391", "r398", "r682" } }, "bdtx-RevelioTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "RevelioTherapeuticsMember",
"presentation": { "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"; "lang": { "en-us": { "role": { "terseLabel": "Revelio Therapeutics", "label": "Revelio Therapeutics [Member]", "documentation": "Revelio Therapeutics"; } } }, "auth-ref": { } }, "ecd-Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "terseLabel":
"Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]"; } } }, "auth-ref": { "r565" } }, "ecd-Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]"; } } }, "auth-ref": { "r565" } }, "bdtx-SaleOfStockAuthorizedConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "SaleOfStockAuthorizedConsideration", "crdr": "debit", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFFPRESENTATIONDetails"; "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, authorized consideration", "label": "Sale of Stock, Authorized Consideration", "documentation": "Sale of Stock, Authorized Consideration"; } } }, "auth-ref": { } }, "us-gaap-SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFFPRESENTATIONDetails"; "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, net of offering costs", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth-ref": { } }, "us-gaap-SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFFPRESENTATIONDetails"; "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth-ref": { } }, "us-gaap-SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFFPRESENTATIONDetails"; "lang": { "en-us": { "role": { "terseLabel": "Number of shares sold (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth-ref": { } }, "us-gaap-SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFFPRESENTATIONDetails"; "lang": { "en-us": { "role": { "terseLabel": "Stock price (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth-ref": { } }, "us-gaap-ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"; "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable), (b) other payables, and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth-ref": { } }, "us-gaap-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareDetails"; "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth-ref": { "r17" } }, "us-gaap-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables"; "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth-ref": { "r17" } }, "us-gaap-ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"; "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available for sale [Line Items]", "label": "Debt Securities, Available for Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": { "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159" } }, "us-gaap-ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables"; "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Net Loss per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings-per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth-ref": { "r601" } }, "us-gaap-ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": {
"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"; "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment

Arrangement, Expensed and Capitalized, Amount [Table]], "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r24"] }, "us-gaap-ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r24"] }, "srt-ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": { "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails", "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "auth_ref": ["r179", "r180", "r182", "r264", "r577", "r578", "r579", "r658", "r659", "r660", "r661"] }, "us-gaap-ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": { "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain names defined in one or many axes to the table." } } }, "auth_ref": ["r111", "r179", "r180", "r182", "r183", "r308"] }, "us-gaap-ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": { "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": ["r86", "r111", "r179", "r180", "r182", "r183", "r308"] }, "us-gaap-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value: Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value: Assets and Liabilities Measured on Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r664", "r665"] }, "us-gaap-ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r5", "r332"] }, "us-gaap-ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r224", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253"] }, "us-gaap-ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted average grant date fair value." } } }, "auth_ref": ["r8", "r9", "r66"] }, "dei-Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r490"] }, "dei-SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.blackdiamondtherapeutics.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Name of each exchange on which registered", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r492"] }, "us-gaap-ScheduleOfShareBasedCompensation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "erdc": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "bdtx-ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding": { "xbrltype": "percentItem", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Increase of authorized shares, percent of common stock outstanding", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding" } } }, "auth_ref": { } }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Units forfeited (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r244"] }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleOfRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Cancelled or forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r244"] }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Units granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r242"] }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Units outstanding (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r239", "r240"] }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleOfRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Number of shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleOfRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "periodStartLabel": "Unvested restricted common stock, beginning balance (in dollars per share)", "periodEndLabel": "Unvested restricted common stock, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r239", "r240"] }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleOfRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": { } }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Units vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r243"] }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "erdc": "debit", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair value of units vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r246"] }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleOfRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r243"] }, "us-gaap-ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails";

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": { "r224", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" } }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname":

"ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount", "erdr": "credit", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails";, "lang": { "en-us": { "role": { "terseLabel": "Maximum employee subscription amount", "label": "Share Based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount" } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails";, "lang": { "en-us": { "role": { "terseLabel": "Maximum employee subscription rate", "label": "Share Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": { "r231" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails";, "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Life and Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": { "r233" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": { "r233" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "negatedTerseLabel": "Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": { "r238" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "negatedTerseLabel": "Canceled or forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": { "r237" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": { "r235" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "erdr": "debit", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": { "r23" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding; beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": { "r231", "r232" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding; beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": { "r231", "r232" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "erdr": "debit", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Options vested or expected to vest, intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r247" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Options vested or expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r247" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Options vested or expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r247" } }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "presentation": { "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails";, "lang": { "en-us": { "role": { "terseLabel": "Award purchase period (in months)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Period" } } }, "auth_ref": { } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails";, "lang": { "en-us": { "role": { "terseLabel": "Shares issued under share-based compensation plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": { "r23" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails";, "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": { "r236" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": {

"http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails";, "lang": { "en-us": { "role": { "terseLabel": "Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": { "r238" } }, "us-

gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Cancelled or forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth-ref": { "r237" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth-ref": { "r235" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1", "erdr": "debit", "presentation": ["http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Options exercisable; intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth-ref": { "r23" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, remaining life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r23" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, remaining life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r67" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Options vested or expected to vest, remaining life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth-ref": { "r247" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": ["http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Maximum percent of fair market value of common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth-ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": ["http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "negatedTerseLabel": "Surrender of shares for taxes (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth-ref": [] }, "bdtx_ShelfRegistrationStatementMember": { "xbrltype": "domainItem", "nsuri": "http://www.blackdiamondtherapeutics.com/20240630", "localname": "ShelfRegistrationStatementMember", "presentation": ["http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "lang": { "en-us": { "role": { "terseLabel": "Shelf Registration Statement", "label": "Shelf Registration Statement [Member]", "documentation": "Shelf Registration Statement" } } }, "auth-ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "erdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESummaryOfLeaseCostandOtherOperatingLeaseInformationDetails", "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.blackdiamondtherapeutics.com/role/LEASESummaryOfLeaseCostandOtherOperatingLeaseInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth-ref": { "r325", "r476" } }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth-ref": { "r7", "r38", "r41", "r42", "r43", "r44", "r45", "r46", "r47", "r48", "r49", "r50", "r51", "r52", "r53", "r54", "r55", "r56", "r57", "r58", "r59", "r60", "r61", "r62", "r63", "r64", "r65", "r66", "r67", "r68", "r69", "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" } } }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "documentation": "Statement of Cash Flows [Abstract]" } } }, "auth-ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "documentation": "Statement of Financial Position [Abstract]" } } }, "auth-ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "documentation": "Statement of Comprehensive Income [Abstract]" } } }, "auth-ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "documentation": "Statement of Stockholders' Equity [Abstract]" } } }, "auth-ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth-ref": { "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730

"r682"}}, {"us-gaap-StockholdersEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"}], "lang": {"en-us": {"role": {"terseLabel": "Stockholders' equity", "label": "Equity, Attributable to Parent [Abstract]"}}, "auth-ref": [{"us-gaap-SubleaseIncome": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "order": "credit", "calculation": {"http://www.blackdiamondtherapeutics.com/role/LEASESSummaryOfLeaseCostandOtherOperatingLeaseInformationDetails"}, {"parentTag": "us-gaap-LeaseCost", "weight": -1.0, "order": "3.0"}}, "presentation": [{"http://www.blackdiamondtherapeutics.com/role/LEASESSummaryOfLeaseCostandOtherOperatingLeaseInformationDetails"}], "lang": {"en-us": {"role": {"negatedTerseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense."}}}, "auth-ref": [{"r327", "r476"}]}, {"us-gaap-SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."}}}, "auth-ref": [{"us-gaap-SubsidiarySaleOfStockAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock."}}}, "auth-ref": [{"us-gaap-SubsidiarySaleOfStockLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Subsidiary, Sale of Stock [Line Items]", "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, "auth-ref": [{"ecd-TabularListTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"terseLabel": "Tabular List Table", "label": "Tabular List [Table Text Block]"}}, "auth-ref": [{"r545"}]}, {"ecd-TotalShareholderRtnAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount"}}, "auth-ref": [{"r537"}]}, {"ecd-TotalShareholderRtnVsPeerGroupTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]"}}, "auth-ref": [{"r544"}]}, {"ecd-TradingArrAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]"}}, "auth-ref": [{"r564"}]}, {"ecd-TradingArrByIndTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]"}}, "auth-ref": [{"r566"}]}, {"dei-TradingSymbol": {"xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/CoverPage"}], "lang": {"en-us": {"role": {"terseLabel": "Trading Symbol(s)", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange."}}}, "auth-ref": [{"us-gaap-TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTScheduleOfFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"}, {"http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."}}}, "auth-ref": [{"r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r213", "r215", "r282", "r305", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r383", "r466", "r467", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r478", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r620", "r621", "r622", "r623", "r663", "r666", "r667", "r668", "r669", "r670"}]}, {"ecd-TrdArrAdoptionDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date"}}, "auth-ref": [{"r567"}]}, {"ecd-TrdArrDuration": {"xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration"}}, "auth-ref": [{"r568"}]}, {"ecd-TrdArrExpirationDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date"}}, "auth-ref": [{"r568"}]}, {"ecd-TrdArrIndName": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"terseLabel": "Name", "label": "Trading Arrangement, Individual Name"}}, "auth-ref": [{"r566"}]}, {"ecd-TrdArrIndTitle": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"terseLabel": "Title", "label": "Trading Arrangement, Individual Title"}}, "auth-ref": [{"r566"}]}, {"ecd-TrdArrSecuritiesAggAvailAmt": {"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount"}}, "auth-ref": [{"r569"}]}, {"ecd-TrdArrTerminationDate": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date"}}, "auth-ref": [{"r567"}]}, {"ecd-UndrlygSecurityMktPriceChngPet": {"xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPet", "presentation": [{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}], "lang": {"en-us": {"role": {"terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent"}}, "auth-ref": [{"r563"}]}, {"us-gaap-UseOfEstimates": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"}], "lang": {"en-us": {"role": {"terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."}}}, "auth-ref": [{"r148", "r199", "r20", "r76", "r77", "r79", "r80"}]}, {"us-gaap-VariableLeaseCost": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "order": "debit", "calculation": [{"http://www.blackdiamondtherapeutics.com/role/LEASESSummaryOfLeaseCostandOtherOperatingLeaseInformationDetails"}, {"parentTag": "us-gaap-LeaseCost", "weight": -1.0, "order": "3.0"}]}, "presentation": [{"http://www.blackdiamondtherapeutics.com/role/LEASESSummaryOfLeaseCostandOtherOperatingLeaseInformationDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."}}}, "auth-ref": [{"r326", "r476"}]}, {"ecd-VstngDtFrValOfEqtyAwrdsGrntdAndVstlnCvrdYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstlnCvrdYrMember", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"}}, "auth-ref": [{"r533"}]}, {"us-gaap-WarrantMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Warrants to purchase common stock", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."}}}, "auth-ref": [{"r479", "r480", "r483", "r484", "r485", "r486"}]}, {"us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited"}, {"http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."}}}, "auth-ref": [{"r128", "r133"}]}, {"us-gaap-WeightedAverageNumberOfSharesOutstandingBasic": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [{"http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveLossUnaudited"}, {"http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Weighted average common shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."}}}, "auth-ref": [{"r127", "r133"}]}, {"ecd-YrEndFrValOfEqtyAwrdsGrntdlnCvrdYrOutsdngAndUnvstdMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdlnCvrdYrOutsdngAndUnvstdMember", "presentation": [{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": {"en-us": {"role": {"terseLabel": "Year end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"}}, "auth-ref": [{"r531"}]}]}}, {"std-ref": {"r0": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/21474477401/830-230-45-1"}, "r1": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/21474482790/220-10-45-10A"}, "r2": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/21474482740/230-10-45-14"}, "r3": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/21474480429/718-10-50-2"}, "r4": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/21474482740/230-10-45-28"}, "r5": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r6": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147481203/810-10-50-1A"}, "r7": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/214748112/505-10-50-2"}, "r8": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480429/718-10-50-2"}, "r9": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480429/718-10-50-2A"}, "r10": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480429/718-10-50-2A"}, "r11": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480429/718-10-50-2"}, "r12": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "1", "SubParagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147480566/210-10-S99-1"}, "r13": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482790/220-10-45-14"}, "r14": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482790/220-10-45-14A"}, "r15": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r16": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r17": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482662/260-10-50-1"}, "r18": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482861/275-10-50-4"}, "r19": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482861/275-10-50-8"}, "r20": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482861/275-10-50-9"}, "r21": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(a)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r22": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(c)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r23": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(e)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r24": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(f)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r25": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(g)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r26": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(h)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r27": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(i)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r28": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(j)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r29": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(k)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r30": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(l)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r31": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(m)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r32": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(n)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r33": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(o)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r34": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(p)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r35": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(q)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r36": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(r)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r37": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(s)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r38": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(t)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r39": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(u)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r40": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(v)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r41": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(w)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r42": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(x)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r43": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(y)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r44": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(z)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r45": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(aa)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r46": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(ab)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r47": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(ac)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r48": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(ad)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r49": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(ae)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r50": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(af)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r51": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(ag)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r52": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(ah)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r53": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(ai)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r54": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(aj)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r55": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(ak)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r56": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(al)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r57": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(am)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r58": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(an)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r59": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(ao)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r60": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(ap)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r61": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "SubParagraph": "(aq)", "Publisher": "FASB", "URI": "https://ase.fasb.org/1943274/2147482099/360-10-50-1"}, "r62": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

RXX%J4C4%J4H9H10U M92W2V61#*RYDONTN18-8Z9+>Q*V0XV+QFBTBDTQ3.HRD?2B9B;P6 Y#NR#1+MO0B+80&>Z*MM42&N.RW%AL E@06;H8=IM+H9.H4E.V02T(ODC)XJ7W;
 M92IE.WU>J4H1RBO4U@8-0-0-0A1<=>02GA6G@Q15K4V1.L24ADO%[8-Ms28X0U#SR-M459N+U@OE-ElS#KXMYD50514)YY#FF35G1B7V6D74Z& M88.HE.M7C1M1HEHMI-ROIGC2
 L1E"R8E/K4406V">T1T-TYPKF8Z+&30%JS M7Z1C1H@/OPD>2>YIG3+&B&Z22?&K1EYIE J1P9X.ZL7.0>TETX5K&S.WOE/L0.NFTT2W>60T>P#>#JH2C.M1P&S4Y11L4I1E1H1CIBZ*OC0%
 UJWUJXUJ4N3j31+1B1P1#3CHWFMGR<M9PUGG.W8U>A<41#AK^ELO6=(2X0VMUD9E.O06I=8 TUUQKPKDZ.UZ7
 M6S%2FTA.K.66K%CT=P3F5D+7<5F8R60+0.GC.P4.Y9.WIWR.LB.01.WIGSIO.M0K%9W"6L(=IOWYE2NW6<IQ(=0<15YXIFS?%6 FR#F.SFOE@VDM&SHM.M>J5G
 sHJ).DE.W+48H5.P80HD14CD4M14D1#04049YX1Y4Z?V7MTO<7E.F.KATIXEHYH1P"M*X"X BL17=5WGZ0B1G.M.ZCZPLDLEIV4GTC+M/KC.NT5XUZH1+1)M/MJ/U.OOF5.16=1T5.U+12
 <2 M7.Y1Z/Y2.M1M0Q0&Z?F9XS&7AD1P1J98>=11 0UYT1 4UJ1P1#1 (R@=0O4R<+1 3U5U+UW1TUSI.M6MG30I.A4 HERTNGA4G6UPKFM.IB.Z-RWA#G20Y-NK262Y21+GS21MPOG
 M&=HFFZ<=>UDG<PR.KM.M04A.XMHW&QOND.UY<12+1+GV(E)AHJLXCF=15MP.M2<=>D%W1MAUGORDC&C%SM7IEUVR1&OO4U+>4H00S&A&Z&@TP*GSEVM.MHW+76R&U
 M=&S&ZUJY7Z2W5PWVEX18RT6M.PD51.SBWBGVK>+>12+1+C%>H7HOOLXAF1IC2<=>5WLM11.0C2Z1ZYS.M"C#>4200B2833B5<=>1S18T1H7S.9DFV%>DV>@>4T0.11P0D>P@V>\$T3GCT
 MBCC(=E.LL.L1+EH%>DOJRVH3J3-V&BZXITF?72&Y\$>D1K /SXGZY/M81G.H.R1&PWIF.%N1ZV\$<L.PUK82YD.V.U4.LA#<FPO.C.Q3)PZ?71M2P1! T#
 !-#FP91J91A10Q7@J1WE314%>#P%GN+3YD&P&HDOACW448X.MCZ?67P/VSTG3G1M<=AD1L%U#KVFMC/G2TEVDRK021P.FICB3TH4U4P0.MZ
 JAR&XG.Y.BAJOYFPM38-1BTOK.#6%IB.9.IDP.128=NB2C2VY11T.MAG1ZMTOHV9R7GMW0?7.3&G&DHF+RNH5R<38C.6CMH58M=M<019.2.9.
 M0US&B03<UEFA=M+Z+0HFS&R1D5P88U.#9N%EG3.SJF<=&8B9F.OVG\$<=>M%+>1NDJ0DPROT2.YE-V70U10XR&ZF.M.GA\$5B&F(P5>=>1.#MUYB#NF33Q0E0R000&80*
 (H=HAD67C&7?<L.X.&.#1PCTV7?>#P8.M4.P1.1 40HA&M.P1F82.1XODL0<@>#H#Z>14APBS&F7DH53X1YX9C91Y0R#Z?7 M*F167111011"ON1MYTH0.XX(FSKS89&Q000
 I9X&CD)&JH16J"EK.M4<524S.AA.E6HG&1S807PPP1H1WQWLE1#< G.W47B1P.1#<=>1>+P@MER.MU1. "YF&F%<=>1D&1+YX1.FE0.3"ILESV7W2Y9E@&O1610.01V1YISY&S
 M729KFG&61&0?>7QV?FINOM4M1VZ1&1WSOTW1R.Q.W7C.LE=1W1OJW.M1K.MY&#TMMU<@>(5P9KZ1NU1@=>14&1+L@.VJ ("K1H9R?2QJ.3P.7T&K&4.M.OJ1K&X&1JBV<+>V
 B\$%ZA>UQNE.UMA<=>@J8S81.12117%\$F<=>@X8REFU1#>#H<@>C=69@.X%0.GUGR<@>USGWEF9QV1.M@C.1\$HYZDF.1\$#YD.0<K%#R.X@<G>J..#H%CA<@>00A.LD.(NU.O&I
 M50+GH1D%K0<J.DV1D@66G<=>3.BZ>9>#54>1..M\$R."V1OM"V.F.C1.MIRZZK10H0A."X.A0 7#<@>C/G#00Q7Z1D214C1N10J1B1T1D1B&G1+11M9E.M1JZ1%1Z74.G@>U11.#1
 D6U1U70?>\$Y81705071<46H<=>N.BZ.MEAY11J135.1P@?FH9EYLU1U3VNO6E4)XU3EAP.#T#X.RJYJ<=>C9S.M4R6<=>AWK3N2CNUHG.MT.IG4B4P.2QS.IJ8G<=>CJGWS<=>Y%7.L\$A+7I
 MQUH1D.D.GC8.4911244K(N1)E174C4<=>O&Y1#1DHQI0Z190?>70US5+8&=>M.KQZ0W.K4#K1D@.R111.%01D2130J1UT8Z<=>0.PA3A.BMBU1BT.H=71M3132S)?
 !>DO.X02.G4.N1X1T8%&3BP1+Y(O1P11P7>9IN&2G.B10..M39T1.#P9G325Q<45&+<C&SV1.B62%>KOWP1+<=>SYG&ZOP323R1R2>7RG.M14.0.TK5%114.VGW78AV7<@>S@N1.<3W1
 <70S)JEF.(VYF16".93Z7773273JHU0K.M4<0M5&17.7K/F1X?OQNZ1F&@>C1F0U087X&RTM@RR-RVNVN&H.L116.MAKNZL6&1Z021+*2L.MW1>1+2H1J9S.Z614.1+01YYWH@>SOC
 >M1.O.1Z5+1%WS)E@31\$."RR0>B1K.M.68.2>.&C13NDYAP16G>P>3+<K1>12R0E14(GORP1.IZ146-V+>S6F1.MCGM.H.D.PC<=>=>ASVOTWJ9E.CM2IOZ1N1S.V3ZV"ZB"
 @>H10"UGOY"X1H.Q>G.C.G&@J.D2<=>+G.B.MA"K1W.+9.EDH0&KZFA2PZ.G.EH18.FY91+<=>XW>92T1M10H(=M@>A<=>FDKX1912<=>HD1L.UF9YF+OXN<=>=>N@V.9\$Q.XE&
 @>H8M19M1JLU4M2<9@<0<17)1S1LCWQ6DS?5Z&#H%..>K1>@>DOV#9%0<ZC8.D.FU@T3.M1X&E@>=76.31#<C&G0.3CD*WP?2U@>S@>31(M.P1.WH1N1B.M%ZDKV1
 CGK5Z<=>C1\$ER1F3.Z3T2>5P2.TPM1HXO@>M.MTJ1775EQ&F.&@>Q.L1N1N&1TAZM451<4CS<C#>1.#J1@>SHD<VZ.M2.X0V07V7B&1F19R.&P1J.X30P1JH02&S1J<=>A1V12UGHS.G9V%NTOY
 M%1.L1T1H@>0.9WPW.P.051.OCL1A21D1.D1M1&B191=<=>M1J1XEFX1AMR.9.L1+<=>RRTL01"02M0Y1U&X2WY1+1Z?>#UN11=">A.MJYV.F&Y1Z.<@>IQMC.(BF>5.SKOT>PRS(M2Y3X)<=>C<87
 11N7P010<=>L6&S.MS1>010Y(R&K)JYZ1+T.E&S.LM1QL&SYWKZ&D1JAT51&VZ10J2711.M1F&E&S<=>V4.M47&1&S+0<0"U1B1P1B2?>J&S.Q0<=>MB7.037+190Z.YUHXH@>2A.11.ASN16<
 <V4S>36K?188<=>0.K60<=>19D5>RT11+T.V4.M.6&D1J.L0Z11N%16.A0A2RZ21%>CA071Y.FQDR.#>#>S1D3UX0C3.<=>+8.0.02.MT(ODC1)01->MD.VT<=>8V3&G5D141Y3P<=>2SGFąW>.B#10.(Z2
 G0&356T<=>MIT<=>JW&S<=>01.YD.UF1Y1.M6GM1M2N7<=>41.IW>R7>.>7)3&2<=>1<=>Q0&S4D21EJ5&8&K&SZ2T.B61G.M606E1+5VAR61.MPNP49<=>H1A9Q413P7&M4>+>11(N1P1JGXSFX5ABX?7
 Y021219<=>9.M&M0&Q9H4A@R282&B1#9.E16&3P1JF6.YHON29.C&S@RM0Y011F>D>K1.M\$>+>GUG>2>844.P10N1M1SV.R1V2H1V1<=>B119R12KT15D11.B6U5V%>MBAL."#&FEB<=>B2
 =.01#M5

[illegible]

J8< -@'&V#1.M@FZUL>68SA#OR@IG6#B.7XJ2J3RZ2ZYF05LT7%KHX(B.1740)#!&1KX M=TNK#YFIFKJAJ2X'B W@0MK%A&SD3G\$9Q)BG%D2<?>N M@LF3XN7#8M!9G'+L9 \$U
60+H#*2V\$<@-@1QV2+UEV1HJB1W.3UCAY MP.U#MAM8RH1P2J#1L6-B%GA8N#CYAKS8=-BF7UIGBFP4#P/ \$ M/LWXSV N814@XHLA6EMGC@YH0Q=;
/H2&=BD5W@KHDXVO@1KG=1'J'5 MFLAZ GIN\$ELH#M0#GDZ9U)3L2@64# "BXR>B>#6".LS3M&..TD0V)7.0W M:MO5..SV&+C3LA7.5L&B1=55=1N3@JRZ"D/H1H-
/H2&ID.H">&U2.M0=1+&QZY&1G4SIFK.8(^1)@P7AKF.

~~11D6L+ "0*.@XEDBT0KXG)G2M2.N0S#)D8X"CSW^B.=KF?R4PQ=AYD8" MJ RD*47^H(2R4V^<5>XPI.@66%B1>XT>.^ZCC#)0Z(B*)"C0 MI0Q78~.0sQQ_KZDI65.2;.(^B(4I6VRC)Z8.@JH%O/GX)L.TG_LV~~

60RBP;HB05<8B7F/M2^E7> CW~U+V/A028^H1+H5:5+BU<?2U6?7~U+1**Q MH~IE3T52U7.T.9PM%Q(8#~J/2Z7HZUKW/==<^A^N^J^M
 <GMM-22VHS<78Y/NAA+1+1+5>+0+V/CFZ^L% GU~S,2,HGTJZ<5HJH MX6N,WQIP&W,8%> 0^R~AA&JDDVDNDN>4& 4. Z0ZMS4A6D<D<CJO=XDVX M8X%5WF>QE=3W0\$7
 XYB<S.L4T.76W/5L%>2270@YM30F \$4.D<S%B41&G MSTSBEF7N<^G+HW_VKVZRN6OTUL2I8J+50>8/ BDL7D<2^12@59 _<2K0<XS&HTCJO^NW^ _WIRA.O
 MAA :15~4I9367&S<G<^GIG<^/B1#ZIF6%0<4^~C7CJO.^H.B<~MN7N^T M7I061ASQIH7J1A^E2N1C1H1DEAS0^@<VU<C+P67Z0^@<M1CH.L1/0IV5XZ184E^<DVMXC%7HI3PY
 ^RWR&H5+VH^J^H5+1^HN. OT3 KM3.J32<IOA>+?>Y+3>.<W&WYRO.EFM^M^ MFKC.O%T+&85.2R18 6%>|T+>+OH9\$QSXCXP^UW^11VCY2Y&C<0<3 MOL>VJ+9+.#~:1
 7J=NN<YWB.~#<SS&9ZFP+V^<2VQ<8 #11.92P<IOUA M59 STW>77L5T/ROU.X1(2 R.E/N 7I<#H3D.6I# Y8K Q3& \$PVX>2Y6NM6N3<@&2^OR22
 J5(S1&V1.P=5.DI21&21V1&JAS86=2881.T30 D&W^ XJ1.K&8<9&87&D^Y1@XF@F91^U0029F@NOCQ.8ML6&5^<A^T4T0S
 MSMK@Z L1P.6^R08(I ^S1U1P8@<X@4XZFM^P3T^ONUMCQ^8^V=OQF^N1J1D^M^J^<C^@C@U270~W#<IG.OU.4Y^K<32^ V00SVLJ<O<=V1#3 G.#f1A1
 M1^#K^~5X5M6D80<YROS@K^F<3^H^HPXCSB^HNVC4<X.#.#(1+1<1^1^1^%S M<@>~*%I9Q.60%Z<^4# M+OBG1&N^H G<^O+3\$8D.DDPLN<6^H^M@<F.T.1\$F^8\$= RB1#<^
 XG7@<M=ZG9N%<^1W.9Y Y&@<YU^<T51^1#8%U^169~W+2^GMXC9^4&W5Y&A\$#<M^ MWB1PAUQ<CT%#B2N\$<SMU^R^F25.K(\$%7^GBC+BCGMQWU4K<^*2^NXW^B#&^@583NR>_0T
 M62^HLZ.R01N<C5#>86109.YYK<^O<K&Z%U.BB&H9EY4B\$T2J\$0 1^M^ M6B74MA8<UCB2H5<@3LCS#11MUS&^/C6@3C^D3^6<3^3^3^LC^W0&+1^7^BM1VY
 M0^AUU.~L6R<@^*^A1&^N>#<P1&S<@MRD#1^L^|VIOE0^Y^C4FCAGZ%A A0P^YB<M2~<20P1&CPR&A0^<P1^<7>X&S<@<C3.6&S<@#^X^XNN+D
 M1^+Y.~L<K19Y^FA0A.DB1^KNYJ7T7+LJ^J~ P^RYW2W~+74<2^K&E1& M^UN1.20LP.LD<L1VY^Y3L&87H1AA^&121.MS3\$S@<
 5CK.K\$<MASY0YIKG<6^OVP<+9V9YVH^M^MV8H<^@5#P^HE17 2VX M19C8R@<H^C<P&S@Q\$181U.2BFY59XH^<A>WYI^YHHA79MG\$7A2 M^>NK<
 &E4K.~<3J1R16<P^DFT16>1KJ31<3C4Q114>+?> M5P&V1%HOZ ^1K2&^A^1. J3L1L1ZE9^7+|=~XWOL^NC7U0^+1<GOUN84V IY5Y88^909<^<9C^P1Y1J3E.E>D M1<3>^<E^IE
 4&S<O@<3FXJ^G01P+1^BKR=Q&E^#6#1J1ZBC^H^F.BXW&P3D1 M1PJO&KH1H\$F321WR+34UC 0Q^>LEQ=TS~AWH13DYGC<C05YN^UKOV& M7&7M&^>EW1^IE9297A1
 Y>L7^TLAT&F1UHK ^/WJW1J3X^D7X&Y P0^2D<~ MDP~<T HCG19^29.2YV&#<N^>N1YUO<^DAGC1^H^UHZOD0W 9&1^@PW M<8WZ<
 <J5PJO1LMN^YU640L J7SP7S02&2&N^U^Z4EN^W 6<1B9W^Z&? M4^#<1P4BHQ>+1^V^B1>ZXICK&AK^X^XLM^@UPMQ2&^JN333A6K^M4YH1@<AJDXVC^=31A+10.12%?<
 N12&5^Y13T7^EDU+1^N<K1C<^<O&XA^MS0M2^<802@<@<1&R1V0D7^PA<^#H@LPBROEYS6^E^TMTZ^PYB^QFR8V
 M2^GVZJ^D2S.YLS<M\$<S^T7I^HBCWMA~<LGCN.L1OHA>@TU01A+1VTV06 M5#H^HM6LFA8.C.J5^W^*51JVS10<O>VGK^<VITIK J^KCT<^/DX>%A
 MP9@<@S^<DUGC.L0Q>S5&EABUH^TLV^<+<C<@<X& O1W+<E=M7A>R.7G.Z4Q MG~#1&7=Q.53?S<=S<@<@<+B1+<Q^N4^<8<@<I221PEG5^F<^XJ3^<B M<51UR K)<
 (F=<B\$B>+1.8^7VW4C1A.M5E@<~WE\$F<^IVC<CP6B.YR<616Y^Q M2^<F7^*P M7&L\$X1M12^KX6&=15C&5X<RKB<N1K318^6E^B\$+&A^L M1HWL
 (<A1H^XOD&C1S=E7^#~>?9J04&@PN13 E2ISX5D^F1O.P1M0^M\$<@<@A^F<IR6C>= XYPIH^F0S.NR7Q3U. 0< @<#?2U6.C K59<2Y.G MOI OEZ IZ2^1A:3H^7%>4OE.5I7<
 <28LJ2^SY@<1^Q&RTO0G1^+1V M6%*YL@<1^IF5FO MGH.41L1 OHLY2^E8HLW21~JZ.XH8^Q\$+B/5Y3 M8B%>1YWGQX1XD0U1^+HFI^M&X^U1UHNK^+B4 C4^PT<290K&E11.5%>GXSJ
 MC280.LPW^<W&D5 G QHS^K&B1LZ+<+^U11.^*21 1^>J1&BHMHYD D MD^PVC2B3U>S<#>ELZ07O&UOZL97EJX&JS9%KJHO^@%B&A6CA .04 MC<
 5%<C<^<HJ6I7^GWL<EBCMS5BHH1<3^V^+DH&Z<2C^%K1 8CM<12^>Z M1<C3919RX.D06EQQAQ8Q9XPR<C^C184^GZIGZ<X1W+&K&LEL^FAWIB<^*8^2X<C^WTCZ<^<9&EUHO9<
 MAIL^C9&4V.T\$1@<HWR.60BURLI&E2X^>V^7NI^B1A<+IDD2X^Y&2 Y4 M<=<SBY^EH P14^Z1G1&H&ABIP^S4A0^V1~>+>WXP<RBO^N1.1Z0\$<AVO2J&M1<Z1W^COP8SZR2%O>U2
 INRF21^Y2^F.21 5Z&H&Y>F16 25Y A5FUV= MXXMX<CPD9Y&B<Q^W1W.LG.DFO.89MU2^M.4S>M^IVO<^A0907UJY^G&^XNNA@<EJ^E^<X8BF7W^G.B.Z^H1^=+Z M^1^N1T^A4.L&SV<
 GRO=ZDJPLQ.S9X1 Q1^81<@VU Q1F&K<PTIMHXK^M1M4<N4Z^V2W122AAL.FI\$299PYV<^<1.81<Z\$<L3^81^YI>IGHQO M^<CTGLYDS^Y/L@1Y=BY^H<18GP44^<#<QBBP1^
 8AQ<J3X07DWIH2Z^N\$~P&2 MK M.MHJRs^#Q.TH2\$K^<6&711<C^ V<L@NE6.FBQP^P 7^LE^<2&2W91&OP M%6<@OEJ1^#1<3#6<35%<0^H^R@P1.(21+L^R^B/D^<@V>B0.WD^<B&H
 M7^7Z.EM01^J^<CT7<TKNE~>1X31.HU5O<E#H2% MO1SP078^V4O.CZ1TNGS<+<OYOFIQW^P.Z%Z<8A#>1^/8^ M5<H11&6Y123AB^*M1@<3Y3J2\$<H8H6.R^J\$<M^HIV.RD1.1^<f@<I0
 MOW>2IP74L.G91^<7JN 40XN.S.RSBJN<G<S&S^U2<^V<4C^M4<@<35429.DC.DI 4YB^A^1<1OY3 FCT51~<1XMXL035~<^<B0J+213 MJB1.2.39ZAW1\$% M1^>M^H^<10AV^<A^<BZU.^#6X

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[illegible]

[illegible]

[illegible][illegible]

[illegible]

31-00001701541-bdtx:RevelioTherapeuticsMember 2023-12-31 00001701541-bdtx:RevelioTherapeuticsMember 2024-06-30 00001701541-bdtx:A2020StockOptionPlanMember 2020-01-14 00001701541-bdtx:A2020StockOptionPlanMember 2024-01-01 00001701541-bdtx:A2020StockOptionPlanMember 2024-01-01 00001701541-bdtx:A2020EmployeeStockPurchasePlanMember 2020-01-14 00001701541-bdtx:A2020EmployeeStockPurchasePlanMember 2024-01-01 00001701541-bdtx:A2020EmployeeStockOptionMember 2024-04-01 00001701541-us-gaap:EmployeeStockOptionMember 2023-04-01 00001701541-us-gaap:EmployeeStockOptionMember 2024-01-01 00001701541-us-gaap:EmployeeStockOptionMember 2024-01-01 00001701541-us-gaap:EmployeeStockOptionMember 2023-01-01 00001701541-us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 00001701541-us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 00001701541-us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 00001701541-us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 00001701541-bdtx:OtherAwardTypeMember 2024-04-01 00001701541-bdtx:OtherAwardTypeMember 2023-04-01 00001701541-bdtx:OtherAwardTypeMember 2024-01-01 00001701541-bdtx:OtherAwardTypeMember 2023-01-01 00001701541-us-gaap:EmployeeStockOptionMember 2024-01-01 00001701541-bdtx:A2020StockOptionPlanMember 2024-01-01 00001701541-us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 00001701541-us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 00001701541-us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 00001701541-us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 00001701541-us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 00001701541-us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 00001701541-us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 00001701541-us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 00001701541-us-gaap:RestrictedStockMember 2023-12-31 00001701541-us-gaap:RestrictedStockMember 2024-01-01 00001701541-us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 00001701541-us-gaap:PerformanceSharesMember 2023-12-31 00001701541-bdtx:PerformanceRestrictedStockUnitsMember 2024-01-01 00001701541-us-gaap:PerformanceSharesMember 2024-01-01 00001701541-bdtx:PerformanceRestrictedStockUnitsMember 2024-06-30 00001701541-us-gaap:EmployeeStockMemberbdtx:A2020EmployeeStockPurchasePlanMember 2024-01-01 00001701541-us-gaap:EmployeeStockMemberbdtx:A2020EmployeeStockPurchasePlanMember 2023-01-01 00001701541-us-gaap:EmployeeStockOptionMember 2024-01-01 00001701541-us-gaap:EmployeeStockOptionMember 2023-01-01 00001701541-us-gaap:RestrictedStockMember 2024-01-01 00001701541-us-gaap:RestrictedStockMember 2024-01-01 00001701541-us-gaap:EmployeeStockMember 2023-01-01 00001701541-us-gaap:PerformanceSharesMember 2024-01-01 00001701541-us-gaap:PerformanceSharesMember 2023-01-01 00001701541-bdtx:WarrantMember 2024-01-01 00001701541-us-gaap:WarrantMember 2023-01-01 00001701541-bdtx:OperatingLeasePrincipalOfficeTwoMember 2020-07-31 00001701541-bdtx:OperatingLeasePrincipalOfficeTwoMember 2023-08-31 00001701541-bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember 2020-12-31 00001701541-bdtx:ElizabethBuckMember 2024-01-01 00001701541-bdtx:ElizabethBuckMember 2024-01-01 00001701541-bdtx:ElizabethBuckMember 2024-04-01 00001701541-bdtx:ElizabethBuckMember 2024-06-30 shares iso4217:USD iso4217:USD shares pure bdtx:contract utr:sgfifalseQ2202400001701541-12-31http://fasb.org/US-GAAP/2024/AccruedLiabilitiesCurrenthttp://fasb.org/US-GAAP/2024/AccruedLiabilitiesCurrentP5YYP5YP367D10-Qttrue2024-06-30false001-38501-BLACK DIAMOND THERAPEUTICS, INC.DE81-42546600One Main Street, 14th FloorCambridgeMA02142(617)252-0848Common stock, par value \$0.0001BDTXNASDAQYesYesNon-accelerated

Filtertruefalsefalsefalse56504895328110005621000901600000751790003783000263400012675400013403400015580001730000822000823000205150002198000033700001490.00010.000110000000010000000000000.0010.001500000000500000000050000000046084875604848751645557200070005666940005341870001155000-27000.455563000.

41743100011102100011673600014988600015856700012556000131540002610100027907000957400068780001627500013686000022130000200320004237600041593000-22130000-20032000-42376000-41593000464000539000110100011610001757000341000314100040500022210008800004240001566000-19909000-19152000-38134000-40027000-0.36-0.36-0.52-0.52-0.71-0.71-1.09-1.09551552205515522036516114365161145348203453482034365000853650085-19909000-19152000-38134000-40027000-20000515000-880001163000-19929000-18637000-38222000-38864000-38134000-4002700069900053170001720002360002037000-1300001465000138800038000-370001149000-1434000370000-1561000826000354000-2223000-1659000-1517000-35925000-34399000380009500079000000041886000920320000-1299400041881000514000510002499400002558000051000-23411000763300057044000354830003363300043116000328110004188800082200012280003363300043116000364342975000452503000-1824000-33498900011569500035753903332051000010002477626710002671000648000648000-20875000-20875000365119475000455225000-1176000-35586400098190000018751970326400012646000515000515000-19152000-19152000365335255000457871000-661000-375016000082199000516455577000534187000-27000-417431000116736000880000400000040000004741860008600012502663596400064000641917130001713000-68000-68000-18225000-18225000525276267000540050000-95000-43565600010430600036908328994000209940001689723890003890001819946962500025000753352860005286000-20000-20000-19909000-19909000564084877000566694000-115000-455565000111021000NATURE OF BUSINESS AND BASIS OF PRESENTATION<div style="margin-top:12pt">Black Diamond Therapeutics, Inc. (the Company) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development and advancement of its product candidates identified by its Mutation-Allosteric Pharmacology (MAP) drug discovery engine.</div><div style="margin-top:12pt">The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry. There can be no assurance that the Company's research and development will be successfully completed, that adequate protection for the Company's technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company's product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</div><div style="margin-top:12pt">On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company's common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of \$500 million. The Company simultaneously entered into an Open Market Sale Agreement.</div><div style="margin-top:12pt">SM</div><div style="margin-top:12pt">with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to \$150 million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of June 30, 2024, the Company sold 4,490,853 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately \$25.0 million (\$24.5 million net of offering costs).</div><div style="margin-top:12pt">On July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company's common stock at a price to the public of \$5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately \$71.9 million, after deducting underwriting discounts and commissions.</div><div style="margin-top:12pt">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of common stock and preferred stock. The Company has had recurring losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of \$455.6 million as of June 30, 2024. The Company expects to continue to generate operating losses for the foreseeable future.</div><div style="margin-top:12pt">As of August 6, 2024, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these condensed consolidated financial statements.</div><div style="margin-top:12pt">The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</div><div style="margin-top:12pt">Black Diamond Therapeutics, Inc. (the Company) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development and advancement of its product candidates identified by its Mutation-Allosteric Pharmacology (MAP) drug discovery engine.</div><div style="margin-top:12pt">The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry. There can be no assurance that the Company's research and development will be successfully completed, that adequate protection for the Company's technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company's product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</div><div style="margin-top:12pt">Principles of consolidation</div><div style="margin-top:12pt">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution.</div><div style="margin-top:12pt">Unaudited interim financial information</div><div style="margin-top:12pt">The condensed consolidated financial statements of the Company included herein have been prepared without audit pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of the Company's management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</div><div style="margin-top:12pt">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div><div style="margin-top:12pt">The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.</div><div style="margin-top:12pt">Principles of consolidation</div><div style="margin-top:12pt">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics

Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution. </div><div style="margin-top: 12pt"><div><div style="margin-top: 12pt">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of the Company's management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included. </div><div style="margin-top: 12pt">Use of estimates </div><div style="margin-top: 12pt">The preparation of the Company's condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </div><div style="margin-top: 12pt">The Company continues to monitor the impact of global economic developments, political unrest, high inflation, disruptions in capital markets, changes in international trade relationships and military conflicts, and health crises, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company's business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates. </div><div style="margin-top: 12pt">Recently issued accounting pronouncements </div><div style="margin-top: 12pt">In December 2023, the FASB issued ASU 2023-09. Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company's consolidated financial statements. </div><div style="margin-top: 12pt">In November 2023, the FASB issued ASU 2023-07. Improvements to Reportable Segment Disclosures (Topic 280) (ASU 2023-07) which requires enhanced disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entity's CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. The amendments also expand the interim segment disclosure requirements. This new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this ASU apply retrospectively to all prior periods presented in the financial statements. The Company is in the process of assessing the impact on its financial statements from the adoption of the new guidance and the period in which the new guidance will be adopted. </div><div style="margin-top: 12pt">In October 2023, the FASB issued ASU 2023-06. Disclosure Improvements - Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative (ASU 2023-06). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company's consolidated financial statements. </div><div style="margin-top: 12pt">Principles of consolidation </div><div style="margin-top: 12pt">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution. </div><div style="margin-top: 12pt">Use of estimates </div><div style="margin-top: 12pt">The preparation of the Company's condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </div><div style="margin-top: 12pt">Recently issued accounting pronouncements </div><div style="margin-top: 12pt">In December 2023, the FASB issued ASU 2023-09. Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company's consolidated financial statements. </div><div style="margin-top: 12pt">In November 2023, the FASB issued ASU 2023-07. Improvements to Reportable Segment Disclosures (Topic 280) (ASU 2023-07) which requires enhanced disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entity's CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. The amendments also expand the interim segment disclosure requirements. This new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this ASU apply retrospectively to all prior periods presented in the financial statements. The Company is in the process of assessing the impact on its financial statements from the adoption of the new guidance and the period in which the new guidance will be adopted. </div><div style="margin-top: 12pt">In October 2023, the FASB issued ASU 2023-06. Disclosure Improvements - Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative (ASU 2023-06). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company's consolidated financial statements. </div><div style="margin-top: 12pt">The following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values. <table border="1" style="width: 100%; border-collapse: collapse; display: inline-table; margin-bottom: 5pt; vertical-align: top; text-align: center; width: 100.00%"><tr><td style="width: 1.0%"><td style="width: 1.0%"><td style="width: 1.0%"><td style="width:

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:top">2028</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.926 </td><td colspan="2" style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.324 </td><td colspan="2" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:top">Less: interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4.467)</td><td colspan="2" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,249 </td><td colspan="2" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total lease liability</td><td colspan="2" style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">(4,467)</td><td colspan="2" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23,782 </td><td colspan="2" style="background-color:#cceeef;border-top:1pt solid #000;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>21990004477000459900047240003926000832400028249000446700023782000COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt">The Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.</div><div style="margin-top:12pt">License agreements</div><div style="margin-top:12pt">The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of June 30, 2024, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.</div><div style="margin-top:12pt">Indemnification agreements</div><div style="margin-top:12pt">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2024 or December 31, 2023.</div><div style="margin-top:12pt">Legal proceedings</div><div style="margin-top:12pt">The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</div>BENEFIT PLANS<div style="margin-top:12pt">The Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant's eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three and six months ended June 30, 2024 and 2023, the Company contributed \$152, \$500, \$167 and \$543, respectively, to the 401(k) Plan.</div>10.06152000500000167000543000falsefalsefalse<div style="margin-top:12pt">On May 30, 2024, Elizabeth Buck, our Chief Scientific Officer, entered into a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Buck 10b5-1 Plan). The Buck 10b5-1 Plan is scheduled to commence on August 29, 2024, and will run through August 31, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Buck 10b5-1 Plan is up to 160,000 shares.</div>May 30, 2024Elizabeth BuckChief Scientific OfficertrueAugust 31, 2025160000